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The use of cationic liposomes remains the most attractive non-viral approach in gene 
therapy as these gene carriers provide for ease and versatility in design. In targeted gene 
delivery, liposomes are coupled to ligands tailored to possess desired characteristics for 
improved cell-specificity. Carbohydrates have been established as useful targets for the 
asialoglycoprotein (ASGP) receptor in liver-directed delivery. The main purpose of this 
study was to comparatively evaluate physicochemical characteristics, DNA-binding 
interactions and in vitro transfection activities of hepatocyte-targeted liposomes bearing 
acetylated and deacetylated galactosides in ASGP receptor-mediated gene delivery. 
Furthermore, in silico studies were carried out to assess ligand-receptor interactions for 
both galactosides.  
 
Novel targeted cationic liposomes conjugated with galactosyl ligands viz. cholest-5-en-3-
yl 2-[4-(β-D-galactopyranosyl-1-oxymethyl)-1H-1,2,3-triazol-1-yl]ethylcarbamate (Sc6)  
and cholest-5-en-3-yl 2-[4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-1-oxymethyl)-
1H-1,2,3-triazol-1-yl]ethylcarbamate (Sc9) were formulated with cytofectin 3β[N-(N',N'-
dimethylaminopropane)-carbamoyl] cholesterol (Chol-T) and the neutral co-lipid 
dioleoylphosphatidyl ethanolamine (DOPE), using the thin film hydration–sonication 
method. 
 
Characterisation of lipoplexes by cryo-transmission electron microscopy (cryo-TEM) 
showed unilamellar liposomes, and lipoplexes ranging between ~80 – 140 nm. DNA was 
fully liposome-bound at N:P ratios 2.5:1 – 3:1. Upon inclusion of polyethylene glycol 
2000 -distearoylphosphatidyl ethanolamine (DSPE-PEG2000) in liposome formulations, 
vesicles were more compacted due to steric stabilisation. UnPEGylated lipoplexes 
achieved better condensation of DNA as determined in band shift and ethidium bromide 
displacement assays. Nuclease digestion assays revealed suitable protection of cargo 
DNA by some formulations, with the least protection afforded by the acetylated SM3 
derivatives. Cytotoxicity studies in the HEK293 and HepG2 cell lines revealed good cell 
viabilities under transfection conditions for all liposomes. Transfection efficiency was 
assessed using the luciferase reporter gene assay.  Higher transfection activities were 
observed in the ASGP receptor-positive HepG2 cell line than the ASGP receptor-negative 
HEK293 cells line for all lipoplexes. While the acetylated unPEGylated derivative (SM3) 
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demonstrated better transgene expression levels compared to other derivatives, this was 
not found to be significant. High transfection levels were attributed to favourable size and 
surface charge, as well as galactoside ligand accessibility to the receptor. In the presence 
of excess asialofetuin, a marked decrease in transfection efficiencies was observed for all 
targeted derivatives. 
 
Docking scores further confirmed good binding affinity for the deacetylated Sc6 ligand 
and acetylated Sc9 ligand at ˗6.7 and ˗5.5 kCal/mol, respectively.  The acetylated SM3 
however, achieved avidity to the binding site through hydrogen bonding via the triazine 
linker. Overall transfection efficiency results were corroborated by outcomes from 
molecular studies as both galactoside ligand-conjugated liposomes presented similar 
binding affinities and transfection efficiency results. It is thus concluded that both these 
galactosides, with further optimization could present the potential for hepatocyte-specific 
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1 CHAPTER ONE: INTRODUCTION 
 
1.1 Gene therapy as an alternative therapeutic strategy 
 
Despite great improvements since the 1950s, many of the global health challenges to-date 
remain unaddressed and often present major causatives of deaths worldwide. These are 
unique and multi-faceted challenges which range from lack of basic healthcare, lack of 
suitable methods of practice, and increasing economic pressures due to growing health 
demands. Limitations in conventional therapies such as surgery, radiation and 
chemotherapy (in the case of cancer), coupled with the emerging trend of multi-drug 
resistance in disease-causing pathogens and ineffective use of antibiotics have further 
exacerbated the problem (Websource:www.globalissues.org; Lee and Lee, 2012). 
According to the 2008 World Health Organisation (WHO) report, non-communicable 
diseases such as cardiovascular diseases, chronic lung diseases, diabetes and cancer result 
in over 36 million deaths worldwide each year. The majority of these deaths are found to 
occur in developing countries (Websource:www.globalissues.org). One of the global 
responses in the past decades has been geared towards intensive research in new and 
alternative therapeutic strategies.  
 
A promising approach was established in the past three decades, based on the novel 
concept of gene therapy. The idea of gene therapy originated in the 1960s; however its 
potential and feasibility as an alternative therapy in eradication of diseases was only 
realised in the 1990s (Abdallah et al., 1995; Schmitz et al., 2002; Lee and Lee, 2012). 
The underpinning principle entails delivery of genomic material into defective cells in 
order to correct or replace an abnormality, which in turn restores or presents the cells with 
a new functionality (Abdallah et al., 1995; Martin et al., 2003; Uddin, 2007; Lee and Lee, 
2012). An effective and successful gene therapy requires that the therapeutic gene be 
delivered to a particular cell population efficiently. Thus many of the early gene therapy 
clinical trials reported utilised viral vectors (Li et al., 2011; Lee and Lee, 2012, Gasc n  et 
al., 2013). 
 
The initial focus was to restore diseases and disorders of a monogenic nature, but it has 
since expanded to include treatment and prevention of many other diseases. These include 
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acquired diseases such as AIDS, cardiovascular diseases as well as chronic diseases 
(Stephan et al., 1996; Moghaddam et al., 2011; Zhao et al., 2012). It is important to note 
that more than 1400 clinical studies conducted for gene therapy, almost 70% have been in 
the area of cancer (Figure 1.1) (Choi et al., 2001; El-Aneed, 2003; Uddin, 2007; Lee and 
Lee, 2012; Nayerossadat et al., 2012).  
 
 
Figure 1.1 Statistical analysis of gene therapy trials and indications addressed (Gasc n  et    
al., 2013) 
 
One of the earliest gene therapy clinical trials reported was conducted in 1989 using a 
retroviral vector. In 1990, severe combined immunodefiency disorder (SCID) patients 
were treated using gene therapy (Lee and Lee, 2012; Nayerossadat et al, 2012). However, 
when a patient enrolled in adenoviral-mediated gene transfer clinical trial for the human 
ornithine transcarbamylase cDNA died in 1999, it resulted in a major setback for gene 
therapy (Lee and Lee, 2012; Nayerossadat et al., 2012). There was optimism when 
patients with X-linked severe combined immunodeficiency (X-SCID) were successfully 
treated using retroviral gene vectors. Some of the patients; however, developed leukemia 
due to viral integration, leading to activation of the LMO2 gene (Simões et al., 2005; 
Karmali and Chaudhuri, 2007). While retroviral vectors are still the most commonly 
employed viral gene delivery vectors, low efficiency in vivo, immunogenic problems and 
their inability to transfect non-dividing cells has made them undesirable. Additionally, 
risk of insertion can lead to oncogene activation or inactivation of tumour-suppressor 
genes. Acute immunological responses have limited clinical application of many 
adenoviral vectors to a few tissues such as liver, and lung for cystic fibrosis treatment. 
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Severe side effects and fatalities have been reported in some cases (Simões et al., 2015; 
Nayerossadat et al., 2012; Lee and Lee, 2012). Various other viral delivery systems are 
currently being investigated and include those derived from the vaccinia virus, human 
cytomegalovirus and Epstein-Barr virus (Nayerossadat et al., 2012). However, it remains 
an open question if the application of viral gene delivery systems will enjoy sustained 
popularity.  
 
Regardless of past successes and failures in viral vectors, gene therapy still presents a 
powerful tool in a curative approach to diseases. This has inevitably presented an urgent 
expediency in development of non-viral delivery systems. It has also meant that 
researchers had to adopt a more responsive approach to the challenges encountered, for 
successful application of non-viral gene therapy. Perhaps the most important challenge in 
gene therapy lies with the actual delivery itself. This is dependent on two factors: choice 
of therapeutic gene to be introduced, and the delivery carrier to be used (Schmitz et al., 
2002; Simões et al., 2005; De Laporte et al., 2006; Pathak et al., 2008; Bhattacharya and 
Bajaj, 2009; Elsabahy et al., 2011; Li et al., 2011; Lee and Lee, 2012; Nayerossadat et al., 
2012). 
 
Traditionally, gene therapy has been nucleic acid-based in its approach where antisense 
and RNA interference have been reportedly used in cancer therapy. In use of antisense 
oligonucleotides (AONs), complementary hybridization of these 15-30 nucleotide 
fragments with the target messenger RNA results in its degradation by RNase H. This 
then results in direct blocking of the production of the disease-causing protein. RNAi 
mechanisms rely on the functionality of two small RNA molecules, which are microRNA 
(miRNA) and small interfering RNA (siRNA). Following delivery of these RNAi 
molecules into the cytoplasm, the target mRNA is incorporated into the RNA-induced 
silencing complex (RISC) in a sequence-specific manner, leading to cleavage of the target 
mRNA. In essence, both approaches are successful in that there is translation inhibition 
by downregulation or loss of functionality of the unwanted protein (Sonoke et al., 2011; 
Shim et al., 2013). Plasmid DNA (pDNA) has often been used in restoration of 
functionality of a defective protein by introducing the appropriate wild-type gene. While 
nucleic acid-based therapeutics present with real potential, limitations in application of 
these macromolecules in vivo include problems with selective delivery to target tissues, 
instability in serum and rapid clearance by the reticulo-endothelial system (RES) (Pathak 
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et al., 2008; Podesta and Kostarelos, 2009; Elsabahy et al., 2011; Maslov et al., 2011; 
Sonoke et al., 2011; Zhang et al., 2012; Cheng et al., 2013; Shim et al., 2013).  
 
Improvements in vector characteristics are particularly emphasised as they determine 
efficiency in delivery and expression, specificity to target cells and the immune response 
by the host. An ideal vector has to display minimal toxicity, protect the therapeutic cargo 
from degradation and evade opsonisation by the mononuclear phagocytic system (MPS) 
(Schmitz et al., 2002; Gasc n et al., 2013). Additionally, it must show increased cell 
specificity, and result in prolonged and efficient transfection. In essence, the vector-cargo 
delivery system should be able to travel as safely as possible bypassing various 
extracellular barriers en route to the specific cell population as well as overcoming 
intracellular barriers for expression (Niidome and Huang, 2002; Schmitz et al., 2002; 
Elsabahy et al.,2011; Zhao et al., 2012; Gasc n  et al., 2013; Xiang and Zhang, 2013). 
 
1.2 Gene delivery systems 
 
Gene delivery systems are mainly categorised into: viral and non-viral systems (Safinya 
et al., 2006; Uddin, 2007; Mintzer and Simanek, 2009; Nayerossadat et al., 2012; Gasc n  
et al., 2013).  
 
1.2.1 Viral gene delivery 
 
Viral systems have over the years primarily made use of retroviruses, and adenoviruses. 
Clinical applications of adeno-associated viruses in gene therapy have also been reported. 
The key reason viral carriers were considered for gene transfer was due to their naturally 
infecting or transducing properties (Cristiano et al., 1993; Karmali and Chaudhuri, 2006).  
Viral vectors thus gained research popularity due to higher transfection efficiency 
compared to non-viral delivery systems. However, the many disadvantages associated 
with their use have hindered their application in vivo. These include generation of 
immune responses to expressed viral proteins, integration of some viral vectors into the 
host chromosome as well as difficulties in engineering viral envelopes for targeted 
delivery to desired cells (Cristiano et al., 1993; Aissaou et al., 2004; El-Aneed, 2004; 
Nayerossadat et al., 2012). Coupled to this, is the potential generation of replication 
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competent infectious viruses, the inability to administer certain viral vectors more than 
once, limitations in terms of cargo nucleic acid size and high costs in production of large 
amounts of high-titer viral stocks for use in clinic (Templeton, 2002; Wasungu and 
Hoekstra, 2006; Pathak et al., 2008; Zhi et al., 2010, Lee and Lee, 2012; Nayerossadat et 
al., 2012).  
 
While viral systems have dominated vector systems in the human clinical trials, there 
continues to be robust advancement in development and application of non-viral systems 
to provide for a safer alternative to viral delivery systems (Mintzer and Simanek, 2009; 
Nayerossadat et al., 2012; Gasc n  et al., 2013; McCrudden and McCarthy, 2013). 
 
1.2.2 Non-viral gene delivery 
 
The design of non-viral delivery systems requires an understanding of the various 
extracellular and intracellular challenges presented in their application in vivo (Pouton 
and Seymour, 2001; Khalil et al., 2006). Most non-viral delivery systems have addressed 
the safety issue by making biocompatibility a key consideration. However, there are other 
equally important factors to consider. Perhaps the most obvious problem is that these 
carrier systems are in essence foreign to our bodies. Consequently, there is often rapid 
clearance of the introduced non-viral carrier system (Khalil et al., 2006; Montier et al., 
2008). Thus there is a need to evade the immune response for minimal clearance by the 
system. Another fundamental issue relates to the biological, physical and chemical 
stability of the non-viral carrier and its cargo. The integrity of the carrier system should 
be maintained upon storage, as well as after administration, as this will translate into 
increased circulation time in the bloodstream (Pouton and Seymour, 2001; Yadav et al., 
2011; Laouini et al., 2012). Another critically important aspect relates to intracellular 
delivery to the affected cells, tissues or organs, where adequate levels of expression of the 
delivered therapeutic genes are required (Pouton and Seymour, 2001; Templeton, 2002; 
Montier, et al., 2008; Mintzer and Simanek, 2009; Nayerossadat et al., 2012; Padeganeh 
et al., 2012). Hence, the pursuit in many of the non-viral carrier designs is to address all 
the challenges mentioned.  
While the task has remained daunting, several non-viral therapeutics has advanced to 
clinical trial stage. These include cationic lipid and polymer-mediated gene delivery 
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systems, which have been used to successfully target both genetic diseases and cancer 
(Table 1.1) (Liu and Song, 1998; Ropert, 1999; Mintzer and Simanek, 2009; Zhi et al., 
2010; Lee and Lee, 2012). 
 
Table 1.1 Gene therapy clinical trials conducted using non-viral carriers (adapted from 
Mintzer and Simanek, 2009) 
Disease 
 
Major Carrier Construct Status 
Melanoma DMRIE/DOPE Allovectin-7 Phase III 
Melanoma and 
renal cell cancer 
DMRIE/DOPE Allovectin-7 Phase II 
Solid tumours DOSPA/DOPE Allovectin-7 Phase I 
Head and neck 
cancer 
DC-Chol/DOPE tgDCC-E1A Phase II 
Ovarian Cancer DC-Chol/DOPE tgDCC-E1A Phase I 
Glioblastoma 
multiform 
DC-Chol/DOPE LIPO-HSV-1-tk Phase II 
Cystic fibrosis DC-Chol/DOPE 
DOTAP 
LIP-HSV-1-tk Phase I 
Phase I 
Cystic Fibrosis GL-67/DOPE GL-67:DOPE-pCF1-
CFTR 
Phase I  
Bladder cancer in vivo jetPEI BC-819 Phase IIb 
Ovarian Cancer PEG-PEI-Chol EGEN-001 Phase I 
Cystic Fibrosis PEGylated 30mer PLL DermaVir Phase II 
HIV PEI mannose and 
dextrose 
DermaVir Phase II 
Solid tumours Cyclodextrin-based 
polymer 





Most literature characterises non-viral systems as either chemical or physical, based on 
the nature of their synthesis, and methods of introduction to the body (Table 1.2) (Kong et 
al., 2012; Padeganeh et al., 2012; Gasc n  et al., 2013).  
 
Table 1.2 Non-viral delivery systems for gene therapy (adapted from Gasc n  et al., 2013) 












Calcium phosphate, Silica, Gold, Magnetic 
 
Synthetic or natural 
biodegradable particles 
 
Polymeric-based non-viral vectors 
Cationic lipid-based non-viral vectors 
Peptide-based non-viral vectors 
 
Physical force can be applied in order to overcome the cell membrane barrier and 
facilitate gene transfer. Naked DNA can be directly injected into tissues of concern using 
a syringe. In particle bombardment, a microprojectile gene transfer or a gene gun is 
utilised and DNA-coated gold particles are propelled towards the cells at high pressure 
for final delivery into the nucleus. The latter method has been used in treatment of 
ovarian cancer and provides for precision in DNA doses administered (Niidome and 
Huang, 2002; Nayerossadat et al., 2012; Lee and Lee, 2012). Naked DNA delivery can 
also be achieved by rendering the cell membrane porous and permeable thus allowing 
uptake of DNA. In electroporation, this is achieved by using electric pulses while in 
sonoporation, ultrasound is used. Efficiency in both methods is determined by the 
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intensity of the pulses, frequency and duration. Sonoporation provides a non-invasive and 
site-specific choice. Electroporation has been successfully implemented in cancer therapy 
(Lee and Lee, 2012). Hydrodynamic gene delivery has also been frequently used for gene 
delivery to the liver in rodents. This is carried out by rapid injection of large volumes of 
DNA solution via the tail vein. Due to fenestrae enlargement, plasma membrane defect 
associated with this kind of administration, requires the injection volume to be reduced in 
order to make it more applicable in humans. The most important limitation in clinical 
application of naked DNA is its susceptibility to nuclease degradation (Niidome and 
Huang, 2002; Mintzer and Simanek, 2009; Nayerossadat et al., 2012; Gasc n  et al., 
2013).  
Recent use of inorganic particles has sparked huge interest in their application for gene 
therapy. This is attributed to their nanosize structure and ease in preparation. For instance, 
surface-coated silica nanoparticles present excellent characteristics such as 
biocompatibility, colloidal stability, reduced cytotoxicity and they have resulted in good 
transfection efficiency (Gasc n et al., 2013). Recently, gold nanoparticles have been 
investigated for gene therapy. The ability to modify the surface of these gold 
nanoparticles for enhanced efficiency presents yet another advantage. However, the 
research challenge in the past three decades for all non-viral gene vector designers has 
been in matching transfection efficiencies to those displayed by their viral counterparts 
(Mintzer and Simanek, 2009; Gasc n  et al., 2013).   
 
Relevant to this thesis, only the polymeric-based and cationic lipid-based non-viral 
vectors are discussed more extensively. 
 
1.2.2.1 Liposome-mediated gene delivery 
 
Liposomes are small spherical vesicles which are created from cholesterol and natural 
non-toxic phospholipids. They were first described by Alec Bangham and colleagues in 
the 1960s who noted spontaneous multilamellar vesicular arrangement of phospholipids 
in aqueous solution (Bangham et al., 1965; Dua et al., 2012; Laouini et al., 2012; 
Akbazerdah et al., 2013). These arrangements arise through repulsive forces which sort 
the amphiphilic molecules in such a way that the hydrophobic acyl-chains interact 
minimally with the surrounding aqueous medium. This is further driven by various 
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intermolecular forces such as electrostatic interactions, hydrogen bonding and van der 
Waals bonds.  This results in a central aqueous and hydrophilic compartment, which is 
surrounded by one of more phospholipid layers (Montier et al., 2008; Kulkarni et al., 
2011; Dua et al., 2012; Laouini et al., 2012; Allen and Cullis, 2013, Perche and 
Torchillin, 2013).  
 
The potential of liposome-mediated gene transfer was elucidated by the 1970s, with 
several publications reporting liposomal carrier systems delivering exogenous genetic 
material, RNA and DNA into host cells (Ropert, 1999; Torchillin, 2005). This is 
particularly critical with the hydrophilic and anionic nature of nucleic acids, and therefore 
the unique ability of liposomes to bind the nucleic acids is a crucial benefit in gene 
delivery. This, and other considerations which are discussed in later sections, has meant 
that development of liposomes for delivery of therapeutic molecules continues to be of 
growing research interest (Ropert, 1999; Torchillin, 2005; Mintzer and Simanek, 2009; 
Kulkarni et al., 2010). Early pioneering work proposed that these inherent properties of 
liposomes make them unique and versatile delivery vehicles for small therapeutic 
molecules.  This is attributed to their biocompatibility, biodegradability, the protection 
conferred to their therapeutic cargo as well as the flexibility to trap both hydrophilic 
molecules in the central aqueous core, as well as hydrophobic molecules within the 
bilayer (Torchillin, 2005; Akbarzadeh et al., 2013).  
 
Structural parameters such as vesicle size and number of phospholipid bilayers are used 
to classify liposomes into: 1) unilamellar and 2) multilamellar vesicles. Further to this, 
there are small unilamellar vesicles (SUV), or large unilamellar vesicles (LUV), while the 
phospholipid charge makes them neutral, anionic or cationic (Dua et al., 2012; 
Akbarzadeh et al., 2013; Allen and Cullis, 2013; Patil and Jadhav, 2014). Over time, an 
important classification was developed which takes into account composition and 
application of the liposomes. Thus to-date most literature will cite conventional, stealth or 
long-circulating, ligand-targeted, cationic and immuno-liposomes (Torchillin, 2005; Patil 
and Yadhav, 2014). This type of classification also provides an overview of the 




1.2.2.1.1 Conventional liposomes 
 
From early studies, some of the major problems identified with liposomal delivery 
systems included successful retention of the therapeutic molecules, rapid clearance by the 
MPS, and successful intracellular delivery of the therapeutic molecules. Initial attempts to 
tackle these issues were based on modifying the physicochemical properties of these 
conventional or „classical‟ liposomes to impact on their behaviour and fate in vivo (Allen 
and Cullis, 2013). For example, by changing the lipid membrane components, the bilayer 
fluidity may be influenced. Incorporating cholesterol was found to „tighten‟ or increase 
the packing of phospholipids in the lipid bilayer which would result in fluid phase switch 
to solid phase bilayer. Early studies have demonstrated that using liposomes made from 
saturated phosphatidylcholine (PC) or sphingomyelin presented more stability in the 
blood than liposomes prepared from PC with unsaturated fatty acyl chains. Overall, this 
resulted in better stability and reduced leakage of the entrapped molecules (Immordimo et 
al., 2006; Allen and Cullis, 2013). 
 
Another fundamental challenge in use of conventional liposomes is related to their rapid 
uptake and clearance by the MPS (Allen and Cullis, 2013). This not only results in 
reduced distribution in other tissues of the body, but toxic accumulation in some of the 
MPS organs. By modulating liposome size and charge, it has been observed that this 
influences their uptake by the MPS, particularly in the liver and spleen. Larger liposomes 
were found to have a shorter blood circulation time than smaller ones. These findings 
suggested that opsonisation by the phagocytes depends on the size of the liposomes, such 
that SUVs had a longer half-life in blood than the LUVs. Positively charged liposomes 
have also been found to be more toxic, and were observed to be removed quickly from 
the system. Equally, negatively charged liposomes were reported to activate the 
complement system via a different pathway for clearance (Immordimo et al., 2006). 
While conventional liposomes provided a benchmark, their inherent inability to address 






1.2.2.1.2 Long-circulating liposomes 
 
An important advancement in liposome-mediated gene delivery to deal with the issue of 
longevity, and stability was the development of stealth technology. Long-circulating 
liposomes otherwise known as „stealth‟ liposomes, represents one of the important 
cornerstones in the success of liposomal gene delivery (Torchillin, 2005; Allen and 
Cullis, 2013). 
The necessity to evade the MPS is paramount for efficient delivery. By safely creating a 
physical barrier on the liposomal surface, it was envisioned that there would be 
prevention of access and binding of blood plasma opsonins. This would inevitably inhibit 
interactions of MPS macrophages with such liposomes. Use of hydrophilic polymers was 
found to increase the hydrophilicity of the liposomal surface. This in turn leads to steric 
stabilization and increases their longevity in circulation (Allen and Cullis, 2013). This 
concept has been extensively studied and was based on previous work reported by 
Abuchowski and colleagues (1977) where PEG was attached to proteins leading to 
increased circulation half-life (Abuchowski et al., 1977). The underlying principle 
functions on the assumption that the polymer‟s flexible chain which occupies the 
immediate space of the liposomal surface results in exclusion of other macromolecules 
from this space. In fact long circulating liposomes have been found to possess increased 
bioavailability (Figure 1.2 C) (Torchillin, 2005; Podesta and Kostarelos, 2009; Zhang et 
al., 2012). 
 
Figure 1.2 Developmental milestones in design of liposomes: A. Early conventional 
liposomes with: a) entrapped therapeutic molecule in aqueous core, b) entrapped 
therapeutic molecule in the bilayer. B. Targeted immunoliposomes with antibody that is: 
c) covalently coupled to phospholipid bilayer and d) modified with hydrophobic moiety 
and anchored onto liposomal membrane. C. Long-circulating liposomes incorporating e) 
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hydrophilic polymer such as PEG, and f) long-circulating immunoliposomes comprising 
both protective polymer PEG and antibody attached to liposomal surface. D.  Long-
circulating liposomes with targeting moiety grafted onto g) liposomal surface or h) 
attached to the distal end of protective polymeric chain (adapted from Torchillin, 2005) 
 
Early attempts to increase longevity in circulation were achieved by mimicking the 
erythrocyte membrane by modifying the surface with gangliosides and sialic acid 
derivatives, such as GM1. GM1 was used in combination with cholesterol to construct the 
first long circulating liposomes.  Subsequent use of polyethylene glycol (PEG) followed 
and gained much popularity. PEG is a linear polyether diol comprising the monomeric 
repeat unit [-CH2-CH2-O]-, commonly trusted as polymeric steric stabilizer due to its 
low immunogenicity and toxicity (Podesta and Kostarelos, 2009; Allen and Cullis, 2013). 
Surface modification of liposomes with PEG can be achieved in several ways: by 
physically adsorbing the polymer onto the surface of the vesicles, by incorporating the 
PEG-lipid conjugate during liposome preparation, or by covalently attaching reactive 
groups onto the surface of preformed liposomes. Particles with size diameter less than 
100 nm allow for easy modification with PEG (Torchillin, 2005; Yadav et al., 2011; 
Kong et al., 2012). 
Depending on the molecular weight and grafting density, various configurations have 
been proposed which include the mushroom, brush and pancake regimes. These in turn 
affect surface coverage by the polymer and distance between graft sites. A brush-like 
PEG conformation is characteristic of high PEG grafting, while mushroom conformation 
is observed at low grafting density. The brush conformation has been reported to result in 
more efficient reduction of serum interactions (Figure 1.3) (Immordimo et al., 2006; 




Figure 1.3 Schematic representation of different conformational regimes assumed by 
PEGpolymer grafted onto liposomal surface (Immordimo et al., 2006) 
 
Apart from the simplicity with which it can be conjugated, PEG is more soluble in 
aqueous and organic media and hence there is little impact on mechanism of action of a 
therapeutic molecule. The most widely used method at present is to anchor the polymer in 
the liposomal membrane via a cross-linked lipid such as 
distearoylphosphatidylethanolamine (Immordimo et al., 2006; Yadav et al., 2011). 
Additionally, incorporation of PEG into the lipid bilayer offers a platform on which to 
add targeting moieties. Monoclonal antibodies, Fab fragments and peptides have all been 
successfully used for active targeting of long-circulating liposomes. Use of PEG as a 
linker for specific ligands has also been explored and found to lead to longevity and 
effective targeting (Martin et al., 2003; Podesta and Kostarelos, 2009). The most 
significant properties of PEGylated vesicles are their strongly reduced MPS uptake and 
prolonged blood circulation. This means improved distribution in perfused tissues. 
Moreover, the PEG chains on the liposome surface prevent vesicle aggregation, 
improving stability of formulations (Immordimo et al., 2006; Zhang et al., 2012).  
 
New improvements in PEG liposomes include detachable PEG conjugates constructed by 
mild thiolysis of the dithiobenzylurethane linkage between PEG and an amino-containing 
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substrate. Currently, there are some PEG liposomal formulations that are approved for 
clinical use for Karposi sarcoma and ovarian cancer (Torchillin, 2005; Garg and Kokkoli, 
2011; Levine et al., 2013). The superiority of PEG-coated liposomes has revolutionised 
liposomal drug and gene delivery systems. In fact, incorporation of PEG in liposomal 
formulations has become the gold standard for many biomedical applications, and there is 
continued research interest in use of PEG liposomes (Torchillin, 2005; Kong et al., 2012; 
Zhang et al., 2012).  
 
1.2.2.1.3 Targeted liposomes 
 
One of the crucial requirements to a successful and efficient gene therapy is delivery of 
therapeutic molecules to the target cells, i.e. cell-specific delivery. For this approach to be 
fully exploited, it is imperative to understand the significant steps involved in the gene 
transfer process and how to best overcome the challenges presented (Mintzer and 
Simanek, 2009; Gasc n  et al., 2013). Essentially, the encapsulated therapeutic molecule 
has to be presented to the cell surface. At this step, targeting moieties can be coupled to 
the liposomal system for recognition by the target cell types. After binding to the cell 
membrane for the target cell-specific internalisation, the therapeutic molecules are 
directed towards the nuclear region for expression (Smith et al., 1997; Mintzer and 
Simanek, 2009). 
 
Long-circulating liposomes have also been able to achieve an indirect way to target 
certain tissues and organs. „Passive targeting‟ is a phenomenon which results from the 
reduced uptake by MPS following PEG incorporation, thus allowing passive 
accumulation inside other tissues or organs (Figure 1.4) (Bee and Park, 2011; Zhang et 





Figure 1.4 Targeted delivery of nanoparticles to tumours. Active targeting can be 
achieved by ligand-receptor interactions and passive targeting of PEGylated carriers by 
means of EPR effect (Bae and Park, 2011) 
 
The disrupted and discontinuous endothelial lining in the tumor vasculature during 
angiogenesis facilitates extravasations of liposomal formulations into the interstitial 
space.  There is preferential accumulation of liposomes in the tumour area due to the lack 
of efficient lymphatic drainage of the tumour. In a process known as the enhanced 
permeation and retention effect or EPR, there is improved therapy for the cancerous organ 
as there is slow release of the therapeutic over time. It must be remembered that 
liposomal formulations do not extravasate from the bloodstream into normal tissues that 
have tight junctions between capillary endothelial cells (Torchillin, 2005; Immordimo et 
al., 2006; Bae and Park, 2011; Zhang et al., 2012).  
 
Wide use of targeted liposomes has become validated over the years and targeting 
moieties commonly include peptides, carbohydrates, growth factors, monoclonal 
antibodies (MAb) and receptor ligands. These are commonly attached to the vector, and 
some of these ligands have led to enhanced delivery efficiency (Gust and Zenke, 2002; 
Buňuales et al., 2011; Fumoto et al., 2013; Perche and Torchillin, 2013). Endocytosis has 
been proposed as the main route for uptake of most non-viral systems including DNA-
liposome complexes, and not the direct fusion with the plasma membrane. Once bound, 
the complex is internalised into endosomes followed by release and escape into the 
cytoplasm. However, events leading up to the separation of the DNA-liposome complex 





The most significant advantage for targeting is the dramatic increase in therapeutic 
molecule delivered to the target. Increasing the number of ligand molecules exposed on 
the liposome surface, can also result in improved ligand avidity and uptake (Perche and 
Torchillin, 2013). In below subsections, two of the most commonly employed targeted 
liposomes are discussed viz. immunoliposomes and ligand-conjugated liposomes. 
 
a) Immunoliposomes 
In the last few years, there has been increased interest in antibody-based therapeutics, 
commonly known as immunoliposomes. These make use of immune-system components 
namely, fragment antigen binding (Fab) which is responsible for antigen recognition, and 
fragment crystrallizable (Fc) which play a role in biological activity.  Immunoliposome 
application has being explored for the treatment of cancer since the early 1980s.  This is 
because of their ease in preparation, as well as high specificity. Immunoliposomes also 
presents a “bystander killing” effect, meaning that they can diffuse into neighbouring 
tumour cells. Because of their intrinsically short half-life, the stealth technique is 
commonly employed with immunoliposomes in order to increase their circulation time 
(El-Aneed, 2003; Martin et al., 2003; Immordimo et al., 2006; Perche and Torchillin, 
2013). 
 
Various studies have shown improved transfection efficiency in tumours by use of 
antibody-attached long-circulating liposomes in tumours. In a study on rats with 
aggressive brain tumours, it was observed that their life-spans increased by 100% 
following administration of the epidermal growth factor (EGF) receptor antisense mRNA 
by immunoliposomes. While immunogenicity remains a concerning variable, it was found 
that use of Fab subunits instead of whole antibodies reduced risk. Post-insertion of a 
monoclonal antibody has been applied to commercially available doxorubicin-loaded 
liposomes (DOXIL) (El-Aneed, 2003; Immordimo et al., 2006; Perche and Torchillin, 
2013).  
 
b) Ligand-conjugated liposomes 
Targeting has become an absolute essential in many gene delivery system designs. Apart 
from the most obvious benefit of cell-specificity, El-Aneed et al. (2003) also reported 
ligand-conjugated liposomes to be less immunogenic than immunoliposomes. This 
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approach entails incorporation of targeting ligands to bind to cell-surface receptors 
endogenously expressed by specific cells (Dan, 2002; Shim et al., 2013).  
 
Liver-directed gene delivery may be achieved by targeting the ASGP receptor (ASGP-R), 
which is exclusively expressed on liver parenchymal cells or hepatocytes (Kawakami, 
1998; Singh et al., 2001; Nishikawa et al., 2003; Kawakami et al., 2007; Fan and Wu, 
2013). The incorporation of natural ligands for this receptor to the vector can lead to 
selective and specific recognition by the ASGP receptor. Studies have shown increased 
delivery to hepatocytes following asialofetuin-conjugated nanoparticles versus the non-
targeted nanoparticles. Transferrin is another targeting ligand useful in liver cancer. 
Transferrin is overexpressed in these hepatocytes and PEI conjugated with transferrin was 
found to lead to enchanced transfection in vivo (Kawakami, 1998; Gust and Zenke, 2002; 
Arangoa et al., 2003; Nishikawa et al., 2003; McCrudden and McCarthy, 2013). 
 
The epidermal growth factor receptor (EGFR) is a receptor found to be upregulated in a 
number of solid tumours of the breast, prostate and ovaries. Findings by Buňuales et al. 
(2011) demonstrated that EGF-lipoplexes prepared in their study had resulted in 
nanoparticles which were able to transfect different cancer cell lines more efficiently 
compared to a non-targeted system. By acquiring information about a certain receptor, 
and incorporating its targeting ligand into cationic non-viral systems, enhanced tumour-
specific accumulation of the therapeutic nucleic acid is possible (Schaffer and 
Lauffenburger, 2002; Buňuales et al., 2011; McCrudden and McCarthy, 2013). 
 
1.2.2.2 Polymer-mediated gene delivery 
 
Cationic polymer vectors are synthetic gene delivery vectors are being extensively 
explored due to their versatile nature, as well as ease in design and manufacturing. 
Commonly used cationic polymers include poly(l-lysine) (PLL), polyethylenimine (PEI), 
chitosan and polyamidoamine dendrimers (PAMAM) (De Laporte et al., 2006; 
McCrudden and McCarthy, 2013). The molecular weight of some of these synthetic 
compounds can be modified and also allow for ligand conjugation for improved delivery 




Polymers condense DNA into small particles (polyplexes) which are even smaller than 
cationic lipoplexes. This has been a major contributing factor to their wide use as delivery 
vectors, as smaller sizes are favoured for efficient transfection, particulary in vivo. In fact, 
polyplex formulations using cationic polymers have possibly been able to compete with 
viral vectors (Mintzer and Simanek, 2009; Nayerossadat et al., 2011). PLL represent the 
first generation cationic polymers and their biodegradable nature is an added advantage to 
their in vivo applications. However, PLL polyplexes are rapidly cleared from circulation 
and are found to be mostly inefficient in transfection due to their inability to destabilise 
the endosomal compartments. Incorporation of PEG has led to increased circulation time, 
while targeting has enhanced cell-specificity. Additionally, co-transfection with 
endosome-lytic agents that create the proton sponge effect has resulted in improved 
transfection activity (El-Aneed, 2004; Mintzer and Simanek, 2009; Nayerossadat et al., 
2011; Zhang et al., 2012).  
 
PEI and PAMAM represent the second generation cationic polymers and are an 
improvement from first generation PLL polymers. This is attributed to their buffering 
capacity of the endosomal compartment. This induces osmotic swelling and rupture, also 
known as proton sponge effect – a widely accepted hypothesis over the years. 
Characteristics such as molecular weight, composition of complexes, size and charge 
density/zeta potential influence interactions of PEI and DNA, cytotoxicity and efficiency 
profile of PEI polyplexes are important points of consideration. Increase in length and 
branching results in better condensation of DNA and increased protection against 
degradation by nucleases. This in turn leads to improved uptake. Studies have shown that 
high molecular weight PEI (25kDa) was more efficient in DNA condensation, with 
polyplex sizes that range between 20 – 40 nm (El-Aneed, 2004; Mintzer and Simanek, 
2009; Tros de Ilarduya et al., 2010; Fant et al., 2010; Zhang et al., 2012). The highly 
branched PEIs condense DNA to a greater degree and achieve higher transfection 
efficiency. Low molecular weight and moderately branched PEI was found to exhibit low 
toxicity and fairly efficient delivery compared to high MW PEI. PEG conjugation which 
is employed for steric stability to PEI, and targeting have resulted in PEI polyplexes 
displaying reduced toxicity and improved transfection efficiency. PEI is possibly the most 
prominent polymer used for gene delivery both in vitro and in vivo (El-Aneed, 2004; 





1.3 Cationic liposomes for gene delivery 
 
In 1987, Felgner and colleagues reported use of the first cationic lipid-based liposomes in 
delivery of nucleic acids. To-date cationic liposomes represent the most well-
characterised non-viral candidates in gene therapy (Felgner et al., 1987; Pisani et al., 
2011; Zhao et al., 2014). The most important difference between cationic lipids and 
natural phospholipids relates to charge. The natural phospholipids are either neutral 
(zwitterionic) or negatively charged. Thus cationic lipids, by virtue of their positive 
surface charge, will effortlessly and spontaneously condense the negatively charged 
phosphate backbones of a nucleic acid (such as DNA) to give rise to lipoplexes. 
Lipoplexes are highly structured self-assembling nanostructures which provide 100% 
loading efficiency for the DNA, and also offer protection for their cargo from degradation 
by nucleases. Other associated advantages include biocompatibility, biodegradability, 
ease with which they can be designed and manipulated; and their ability to transport large 
pieces of DNA (Gonçalves et al., 2004; Khalil et al., 2006; Zuhorn et al., 2007; Tros de 
Ilarduya et al., 2010). 
 
The model determining formation of lipoplex formation has been studied extensively 
using atomic force microscopy and cryo-electron microscopy (Ma et al., 2007; Wang et 
al., 2012). The two-step mechanism is initiated when the positively charged amine 
headgroups bind via electrostatic interactions to phosphate backbones of DNA. During 
this step, there is collapse of the DNA structure resulting in condensation or compaction 
where DNA is shielded by the lipids. The second step involves lipid-mixing interactions 
which lead to fusion and rearrangements of the liposomes. Further lipid mixing results in 
cationic lipids which are wrapped around the DNA plasmids. Cationic lipids confer the 
positive charge of lipoplexes to the negatively charged cell membrane by non-specific 
electrostatic interactions. Endocytosis, as opposed to fusion has been established to be the 
main route of internalisation for non-viral gene delivery (Figure 1.5) (Khalil et al., 2006; 





Figure 1.5 Fate of cationic liposome-DNA complexes in cells viz. initial internalisation, 
followed by uptake, intracellular trafficking and nuclear delivery (Khalil et al., 2006) 
 
It entails uptake of macromolecules and particles via invagination processes for 
internalisation into the cytoplasm for nuclear expression. It is believed that endocytosis 
leads to better transport towards the nucleus, thus avoiding to some degree cytosolic 
nucleases (Zuhorn et al., 2007). A number of endocytic pathways are involved in lipoplex 
internalization and include phagocytosis, macropinocytosis, clathrin-mediated and non-
clathrin-mediated endocytosis. Receptor-mediated endocytosis often employs the use of 
ligands which bind to cell surface receptors which are concentrated for internalisation 
(Khalil et al., 2006; Zuhorn et al., 2007). 
 
The polymorphic properties of cationic liposomes are particularly highlighted in one of 
the most important rate-limiting steps where DNA is released from compartments such as 
endosomes into the cytoplasm for transport into the nucleus. As the pH of the endosome 
drops from pH 7 to 5.5, some DNA escapes from the early endosome into the cytoplasm. 
Some of the lipoplexes also escape and dissociate to release DNA (Balasz and Godbey, 
2011). Several mechanisms have been postulated for the release of DNA from the 
endosome, with the most prominent being facilitated by the intrinsic membrane 
destabilisation activity of cationic lipids. Electrostatic interactions between the cationic 
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lipid and the endosome membrane are thought to induce the “flip-flop” movement of 
anionic lipids from the cytoplasm-facing monolayer of the endosome membrane. This 
will lead to the formation of a neutral ion pair with the cationic lipid and subsequent 
dissociation of the DNA and its release into the cytosol.  Incorporation of neutral lipids 
such as DOPE and cholesterol has been confirmed to lead to improved transfection 
efficiency (Zuhorn et al., 2007; Balasz and Godbey, 2011). In this mechanism, there is a 
bilayer “flip-flop” of the negatively charged phospholipids from the cytoplasmic leaflet to 
the luminal leaflet of the endosome which subsequently results in neutral ion pairs being 
formed. The weakening electrostatic interactions between the liposome and DNA, 
ultimately lead to separation and release of the DNA from the complex. Another 
mechanism that has been proposed is the proton sponge hypothesis. This is achieved by 
endosome buffering which results in osmotic swelling and endosome disruption. The 
released DNA is believed to then enter the nucleus for expression (Aissaoui et al., 2002; 
Karmali and Chaudhuri, 2007; Zuhorn et al., 2007; Montier et al., 2008; Bhattacharya 
and Bajaj, 2009; Tros de Ilarduya et al., 2010; Zhao et al., 2013). 
 
The successful delivery and expression efficiency of cationic liposomes also requires full 
understanding of the structure of the cationic lipids and all the governing factors that 
impact on the transfection mechanism. This takes into account the chemical basis of 
cationic lipids, and the resultant complexes formed with nucleic acids such as DNA 
(Karmali and Chaudhuri, 2007). Clinical use of cationic liposomes has been limited by 
their instability, rapid clearance, toxicity upon repeated administration, as well as the 
potential immuno-stimulation and complement activation. These disadvantages most 
often result in low delivery and expression efficiency which is a major drawback for 
liposomes (Stephan et al., 1996; Simões et al., 2005; Karmali and Chaudhuri, 2007; 
Mintzer and Simanek, 2009; Tros de Ilarduya et al., 2010).  Despite the above-mentioned 
challenges, cationic liposomes have in the past 3 decades remained the most explored 
non-viral delivery vector (Bhattacharya and Bajaj, 2009; Tros de Ilarduya et al., 2010). 
 
1.3.1 Structural features of cationic lipids 
 
Cationic lipids are amphipiles which commonly comprise three functional domains: 1) a 
polar hydrophilic headgroup 2) a linker bond, and 3) a hydrophobic domain. Since the 
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successful in vitro transfection achieved by Felgner and colleagues (1987) using DOTMA 
(N-(1-(2,3-dioleyloxy)propyl)- N,N,N-trimethyl ammonium chloride), many cationic 
lipids have emerged. Most cationic lipid structures are based on the common foundation 
features presented by these early liposomes (Figure 1.6) (Felgner et al., 1987; Martin et 
al., 2003; Martin et al., 2005; Karmali and Chaudhuri, 2007).  
 
 
Figure 1.6  The cationic lipid DOTMA showing the different structural components viz. 
hydrophilic headgroup, linker bond, and hydrophobic domain (Zhao et al., 2013) 
 
It is unarguable that a relationship exists between transfection efficiency, cytotoxicity and 
the nature of the components of the cationic lipids.  For example, certain aspects of the 
linker can be modified to impact on how well it is tolerated in circulation (Smith et al., 
1997; Karmali and Chaudhuri, 2007). The most common classification of cationic lipids 
is founded on the nature of these parameters, depending on whether they are glycerol-
based, non-glycerol-based and cholesterol- based cationic lipids (Figure 1.7) (Simões et 
al., 2005; Martin et al., 2003; Martin et al., 2005; Karmali and Chaudhuri, 2007). Hence, 




Figure 1.7 Structures of various transfection lipids classified as: A) glycerol-based, B) 
non glycerol-based and C) cholesterol-based cationic lipids (Karmali and Chaudhuri, 
2007) 
 
a) Headgroup  domain 
The most commonly employed hydrophilic headgroup comprises a tertiary amine or a 
quaternary ammonium group as seen in DOTMA and DOTAP. Felgner and colleagues 
later synthesised a number of 2,3-dialkyloxy quaternary hydroxyl-containing compounds 
and these resulted in better transfection than DOTMA. Several cationic lipids that 
delocalise the positive charge in the heterocyclic headgroups such as pyridinium, 
imidazole and piperizine (SAINT) conjugated to cholesterol have resulted in higher 
transfection efficiency and lower cytotoxicity. Multivalency is introduced by the 
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incorporation of polyamines and spermines. The first multivalent lipopolyamine, DOGS 
(dioctadecylamido-glycylspermine) was introduced in 1989 by Behr and colleagues (Behr 
et al., 1989). These have been observed to compact DNA far more efficiently resulting in 
better transfection than the monovalent quaternary amine counterparts (DOTMA, DC-
Chol and DMRIE). However, toxicity due to the micelles formed presents a challenge. 
This can be circumvented by addition of pyridine and guadinine for better positive charge 
spread (BGSC) (Aissaoui et al., 2002; Martin et al., 2003; Karmali and Chaudhuri, 2007; 
Montier et al., 2008; Bhattacharya and Bajaj, 2009; Zhao et al., 2013). 
 
b) Linker bond 
Linker groups act as bridges between the cationic headgroup and the hydrophobic 
domain. The commonly used linkers include ether, ester, amide or carbamate groups. 
Linkers influence conformational flexibility, stability, biodegradability and toxicity; and 
ultimately impact on transfection efficiency. Although the ester-linked DOTMA and 
similar liposomes exhibited high transfection efficiency, they were found to be very 
stable but toxic. Biodegradability and reduced toxicity was reported with use of ether 
bonds such as in DOTAP, and led to increased transfection efficiency of cholesterol-
based cationic liposomes compared to those cationic lipids containing ester linkers. 
Structural analogues of DOTMA, by substitution of the ester linkage with ether linkers, 
DDAB (dimethyldioctadecyl ammonium bromide) and DOTAP (1,2-dioleoyloxy-3-
[trimethylammonio]- propane) are commercially available. Carbamate linkers are 
chemically more stable and biodegradable. The first clinical trial using a liposome-based 
delivery system included the carbamate-linked DC-Chol cytofectin as it displayed better 
transfection efficiency, stability and reduced toxicity. Another important attribute in 
carbamate-linked structures is based on the theory that when the pH drops in the early 
endosomes, it triggers a disconnection of hydrophobic and hydrophilic portions of the 
lipoplex thus resulting in DNA release. Therefore transfection is found to be higher with 
the use of carbamate groups. Linkers consisting of redox-sensitive disulphide bonds have 
been investigated for stimuli-triggered to favour early release of DNA (Aissaoui et al., 
2002; Karmali and Chaudhuri, 2007; Montier et al., 2008; Bhattacharya and Bajaj, 2009; 
Zhao et al., 2013). 
 
Structural parameters such as length, hydrocarbon chain position and nature of chemical 
bonds that make up the linker have also been reported to influence transfection efficiency, 
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biodegradability and stability of the cationic lipids. The length of the linker, such as the 
incorporation of oxyethylene units between cholesterol moiety and the polar headgroup 
has been reported to increase hydration level, and lead to decreased transfection 
efficiency (Karmali and Chaudhuri, 2007). The added benefit is that side chains for 
enhanced targeting, uptake and intracellular trafficking can be added into the linker 
region (Aissaoui et al., 2002; Karmali and Chaudhuri, 2007; Montier et al., 2008; 
Bhattacharya and Bajaj, 2009; Zhao et al., 2013). 
 
c) Hydrophobic domain 
Hydrophobic domains of cationic lipids are derived from either simple aliphatic 
hydrocarbon chains or steroids. The aliphatic chains can be linear and saturated, or linear 
and mono-unsaturated.  The common variations include branched, acetylenic or cis-
mono-unsaturated alkyl chains. The majority of cationic lipids synthesised thus far 
comprise double-chain hydrocarbons. Length, asymmetry, branching and saturation of the 
chains have been correlated to transfection efficiency (Aissaoui et al., 2002; Karmali and 
Chaudhuri, 2007; Montier et al., 2008; Bhattacharya and Bajaj, 2009; Zhao et al., 2013).  
 
Many studies have reported an inverse relationship between transfection efficiency and 
the length of the chain of cationic lipids. It is stated that shorter lengths, branched and 
unsaturated chains lead to decreased phase transition temperature and increased 
membrane fluidity.  This favours higher intermembrane transfer rate and lipid mixing 
leads to potential disruption of endosomal membrane thus facilitating DNA release (Zhi 
et al., 2010). The shorter chains are believed to confer good membrane fluidity and good 
lipid bilayer mixing.  Unsaturated chains are found to be the best choice for transfection, 
with C18:1 oleyl being optimal (Aissaoui et al., 2002; Karmali and Chaudhuri, 2007; 
Montier et al., 2008; Bhattacharya and Bajaj, 2009; Zhao et al., 2013).  
 
The natural properties of cholesterol have ensured that it is the most commonly employed 
alternative to aliphatic chains. These attributes include rigidity, biodegradability and 
fusion activity. These essentially lead to better protection of the liposome-nucleic acid 
complex from nucleases, enhanced stability and reduced toxicity. Additionally, factors 
such as phase transition temperature and membrane fluidity which play a major role in 
DNA dissociation and release from the lipoplex in endosome are favourably influenced. 
Other steroid compounds include vitamin D, antibiotics, cholestane and litocholic acid 
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(Zhi et al., 2010). There have been recent developments in the use of fluorinated 
lipoplexes for enhanced transfection. This is due to the favourable biological and 
physicochemical characteristics with which they are attributed (Aissaoui et al., 2002; 
Karmali and Chaudhuri, 2007; Montier et al., 2008; Bhattacharya and Bajaj, 2009; Zhao 
et al., 2013).  
 
1.3.2 Factors governing lipoplex-mediated transfection efficiency 
 
There are many factors that govern liposome-mediated gene delivery. The mode of 
lipoplex formation also has a bearing on the physicochemical properties of the lipoplexes. 
Lipoplex size, charge density and stability are among the most important parameters that 
ultimately influence transfection efficiency. Additionally, there are indirect aspects such 
as protection of the nucleic acids from nucleases, use of targeting ligands for specificity, 
and inclusion of helper lipids for avoidance of DNA from lysosomal degradation (Simões 
et al., 2005; Wasungu and Hoekstra, 2006; Wang et al., 2012).  
 
These aspects are perhaps best discussed in the context of the processes they are involved 
in, particularly if they are rate-limiting steps during transfection. It is interesting to note 
the coincidence of the site of impact by these factors and the cellular barriers presented 
during non-viral gene delivery. 
 
1.3.2.1 Lipoplex formulation 
 
Formation of lipoplexes is a highly dynamic process which essentially could determine 
the morphology and ultimately the transfection potential of lipoplexes. Formulations for 
delivery of nucleic acids include SUVs, giant unilamellar vesicles (GUV) and 
(multilamellar vesicles) MLVs. SUVs condense DNA to give spaghetti-like shaped 
lipoplexes which have been found to exhibit higher in vitro transfection efficiency. This is 
attributed to the extreme curvature with small radii, which means that lipoplexes attach to 
cells more easily. The residual positive charges on their surfaces lead to enhanced 
interaction with the cell for internalisation and transfection (Smith et al., 1997; 




Another important trait to take into account relates to stability during formulation. It has 
been found that coexistence of polydispersed size distributions may affect stability. Also, 
poor mixing of cationic lipids and helper lipids will often result in poorly stabilised 
complexes, which effectively leads to low transfection efficiencies (Wasungu and 
Hoekstra, 2007). PEG is often introduced to provide steric stabilisation to the liposomes; 
however, this often leads to masking of the positive charges. Thus, PEG serves a dual 
function in promoting stability and as a result protection of DNA cargo from serum 
nuclease degradation. Adversely, the “PEG dilemma” arises and leads to poor interaction 
of the lipoplex with target cells (Tros de Ilarduya et al., 2010; Kibria et al., 2011). This 
has undoubtedly led to hindered application of PEG liposomes as gene carriers. The 
introduction of ligands for recognition by the specific receptors of the target cells is 
employed to circumvent this PEG effect (Xiang et al., 2012). Additionally, there have 
been investigations into cleavable PEG cationic liposomes, where the PEG is released 
when exposed to the acidic environment of the endosomal compartment (Templeton, 
2002; Wasungu and Hoekstra, 2006).  
 
1.3.2.2 Binding and internalisation 
 
As mentioned, the cationic lipoplex surface charge is inherently exposed to the negatively 
charged serum components. These result in interference of their interactions with the cell 
surface. Targeting by attachment of sugar residues was found to provide specificity in 
delivery using receptors. DC-Chol/DOPE based lipoplexes exhibited improved 
transfection efficiency when they were sugar-linked. This was attributed to enhanced 
cellular attachment and internalisation. In this case, it was assumed that targeting led to 
increased gene delivery to the nucleus (Wasungu and Hoekstra, 2006).  
 
Lipoplex size has been determined to be a major parameter for lipoplex-mediated 
transfection efficiency. Size is largely influenced by factors such as cationic lipid ratio, 
types of liposomes formed, and exposure to serum components. For example, large and 
stable lipoplexes of 700 nm have been shown to resist transfection inhibition by serum, 
while lipoplexes less than 250 nm in diameter showed efficient transfection in the 
absence of serum (Ma et al., 2007). However, while smaller-sized lipoplexes are 
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generally expected to be more efficiently internalized via endocytosis, in vitro studies 
have reported that larger lipoplexes often exhibit improved transfection activities (Ross 
and Hui, 1999; Zuhorn et al., 2007). This can simply be due to enhanced sedimentation of 
the larger particles for maximum contact with the cells. Another contributing factor could 
be that once larger lipoplexes are taken up, the large intracellular vesicles are more prone 
to disruption and release of DNA into the cytoplasm. Contrasting results however, show 
that in vivo transfection with larger complexes is not feasible as the capillary network  
present size constraints in the range of 40 – 80 nm; while in vitro the optimal size has 
been proposed to be between 200 – 400 nm (Khalil et al., 2006; Wasungu and Hoekstra, 
2006; Ma et al., 2007; Zuhorn et al., 2007).  
 
Studies with DOTAP lipoplexes have also confirmed that size is perhaps far more critical 
to transfection efficiency than lipoplex charge or the zeta potential. It is believed that size 
is an important trigger of uptake via a distinct transfection-efficient pathway. However, it 
must be stated that aspects that pertain to particle shape, cell type and even culture 
conditions have also been reported to be involved in selection of uptake pathways of non-
viral gene complexes (Ma et al., 2007; Xiang et al., 2012). In a study on the inhibitory 
effects by non-phagocytic B16 cells, the internalisation mechanism was found to be size-
dependent. Particles of about 250 nm were found to be endocytosed exclusively via 
clathrin-coated pits while those of 500 nm were internalised by means of caveolae 
(Wasungu and Hoekstra, 2006). Internalization pathways have a huge impact on the fate 
of the lipoplexes, which will be discussed in later sections. Various intracellular 
compartments convey certain properties that ultimately influence how efficiently DNA is 
trafficked into the cells until expression (Wasungu and Hoekstra, 2006; Zuhorn et al., 
2007; Wang et al., 2012).   
 
While the DNA:lipid ratio will determine the overall charge density; other properties such 
as complex size and shape, lipid formulation and encapsulation efficiency of nucleic acids 
by liposomes play a role in the colloidal properties of the complexes (Templeton, 2002). 
Preparations of cationic liposomes require that there be a slight excess of positive charge, 
which has been seen to result in higher transfection efficiency. In untargeted liposomes, 
this promotes the interaction between the liposome and the negatively charged cell 
surface proteoglycans. Neutrally charged lipoplexes tend to result in aggregated 
assemblies which can impact on transfection negatively. These large and unstable 
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lipoplexes often result in poor transfection efficiency (Zuhorn et al., 2007; Montier et al., 
2008; Bhattacharya and Bajaj, 2009). 
 
1.3.2.3 Release of DNA from endosomes 
 
Lysosomal degradation has to be avoided if DNA has to successfully reach and be 
transcribed in the nucleus. This is achieved through escape from the acidic environment 
of the endosomal compartment. The hexagonal phase transition of the cationic lipid 
membrane is thus seen as an important process in this regard. Cationic lipids adopt 
various structural phases such as micellar, lamellar, cubic and inverted hexagonal phase. 
This is predicted by the packing parameter, P, where P = v/alc  which is defined as the 
ratio of the hydrocarbon volume, v and the product of effective head group area, a, and 
the critical length of the lipid tail, lc (Figure 1.8) (Karmali and Chaudhuri, 2007; Ma et 
al., 2007; Montier et al., 2008; Bhattacharya and Bajaj, 2009; Tros de Ilarduya et al., 
2010; Balasz and Godbey, 2011; Zhao et al., 2013).  
 
When P is greater than lc, and the area occupied by hydrocarbon chains is larger than of 
the headgroup, the cationic lipid assumes the inverted hexagonal phase. The inverted 
hexagonal and micellar cubic phases lead to the destabilisation of the bilayer structure 
and subsequent release of the lipoplex into the cytoplasm. This phase conversion is also 
found to be instrumental in DNA dissociation from the lipoplex where cubic phase 
adopting cationic lipid systems have been observed to express the highest transfection 
efficiency, even more than the hexagonal HII phase (Figure 1.8) (Safinya et al., 2006; 






Figure 1.8 Schematic diagram showing the organization and phase structure of self-
assembled cationic lipids as determined by the packing parameter, P (Balasz and Godbey, 
2011) 
Helper lipids such as DOPE are commonly used in most liposome formulations as they 
promote conformational change from a lamellar bilayer into an inverted hexagonal 
structure following a drop of pH in endosome.  This results in the destabilisation of the 
endosomal membrane, leading to release of lipoplex. The dissociation of lipoplex into the 
respective liposome and nucleic acid cargo leads to improved lipoplex-mediated 
transfection (Hui et al., 1996; Safinya et al., 2006; Karmali and Chaudhuri, 2007; Ma et 
48 
 
al., 2007; Montier et al., 2008; Bhattacharya and Bajaj, 2009; Tros de Ilarduya et al., 
2010; Balasz and Godbey, 2011; Zhao et al., 2013). 
 
One cannot address PEGylated cationic liposomes in isolation without discussing the 
PEG effect on the phase conversion of these liposomes. Tight intermembrane interactions 
are required between the lipoplex surface and the endosomal membrane.  While steric 
stabilisation of the lamellar phase afforded by PEG is crucial for longer circulation, 
release from the endosome is compromised, as it would have to be dissociated. This poses 
a major problem, which may be circumvented by use of cleavable pH-sensitive PEG 
analogues. Targeting moieties also have to be designed in a manner that they do not 
interfere with the tight intermembrane interactions necessary between the endosomal 
membrane and the lipoplex surface. Improved targeting due to the sugar-linked lipoplexes 
has been reported. However, poor delivery due to poor escape from the endosomal 
compartment can result in lower transfection efficiencies (Aissaoui et al., 2002; Wasungu 
and Hoekstra, 2006; Ma et al., 2007; Tros de Ilarduya et al., 2010). 
 
1.3.2.4 Trafficking into nucleus 
 
Nuclear entry is a major rate-limiting step in lipoplex-mediated transfection. It has been 
hypothesised to take place in one of two ways viz. 1) by passive entry during cell division 
when the nuclear membrane temporarily disintegrates, or 2) by active transport through 
the nuclear pores. Naked DNA is prone to degradation by cytosolic nucleases during its 
trafficking to the nucleus. Therefore transit time to the nucleus has to be as short as 
possible. Once reached, a critical factor relates to the limited size of the nuclear pores.  
The passive limit is about 70 kDa molecular mass or 10 nm diameter and hence even if 
condensed in a lipoplex, nuclear entry is impossible (Khalil et al., 2006). During active 
transport, the nuclear pore size is stretched to about 30 nm. Mitosis is believed to play an 
important role in transfection. DNA enters the nuclear compartment during mitosis when 
the integrity of the nuclear membrane is transiently compromised. However, this is the 
case for in vitro transfection of dividing cells, and does not translate to in vivo 
transfection which usually targets differentiated non-dividing cells. Thus molecules of 
large sizes can penetrate into the nucleus during interphase through the nuclear pores 
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(Karmali and Chaudhuri, 2007; Montier et al., 2008; Bhattacharya and Bajaj, 2009; Tros 
de Ilarduya et al., 2010; Balasz and Godbey, 2011; Zhao et al., 2013). 
 
 
1.4 Uptake pathways for non-viral gene delivery 
 
Early studies had proposed that fusion with the cell membrane is responsible for non-viral 
delivery. However, various studies have indisputably established that endocytosis is the 
major path of entry for non-viral delivery vectors. This was demonstrated by Payne and 
colleague following studies on intracellular trafficking of PEI- and Lipofectamine-DNA 
complexes (Payne et al., 2007; Mintzer and Simanek, 2009; Xiang et al., 2012; 
McCrudden and McCarthy, 2013). There is also a need to develop a comprehensive 
understanding of non-endocytic pathways as they form a significant part of non-viral gene 
delivery. 
 
1.4.1 Endocytic uptake pathways 
 
Endocytosis is classified into two main categories such as phagocytosis and pinocytosis. 
Pinocytic pathways are characterised as follows: clathrin-coated endocytosis, caveolae, 
macropinocytosis and clathrin/caveolae independent endocytosis (Figure 1.9.) (Khalil et 
al., 2006; Morille et al., 2008; Resina et al., 2009; Ziello et al., 2010; Xiang et al., 2012; 







Figure 1.9 Schematic representation of the various internalisation pathways and hurdles 
encountered for intracellular trafficking (Morille et al., 2008) 
Phagocytosis is generally restricted to specialised cells such as macrophages, neutrophils 
and monocytes with the main function to remove pathogens and other unwanted particles 
from the system. While this process does not contribute significantly to gene delivery 
pathways, it cannot be completely ignored for its potential to influence internalization 
(Khalil et al., 2006; Mintzer and Simanek, 2009). Macropinocytosis is currently being 
explored for a possible role in gene delivery and transfection pathways. This is due to 
advantageous properties displayed by this pathway, which include efficient uptake of 
fluid-phase macromolecules and ease of escape from the inherently leaky uncoated and 
larger sized (up to 0.2 µm in diameter) macropinosomes. Most importantly, internalised 
particles can avoid lysosomal degradation as there is no fusion with lysosomes. However, 
much needs to be done in order to target this pathway for gene delivery systems (Khalil et 





1.4.1.1 Clathrin-mediated endocytosis 
 
Clathrin-mediated endocytosis (CME) is possibly the best-characterised pathway for 
endocytosis. It is constitutively used in biological processes which require uptake of 
nutrients, growth factors and pathogens. This is seen in low-density lipoprotein (LDL) 
internalisation by binding to the LDL receptors on the liver surface (Khalil et al., 2006).  
Internalisation of particles in this pathway seems to be size-dependent, with size ranges of 
150 – 200 nm.  This is attributed to the limiting size of the clathrin coated pits which have 
a radius of approximately 100 nm. This is followed by clustering of the internalised 
complexes in coated pits on the plasma membrane. The coated pits then invaginate and 
pinch off from the plasma membrane to form intracellular clathrin-coated vesicles. The 
internalised complexes are then depolymerised in the early endosomes. There is a rapid 
drop in pH from neutral to pH 5.9 – 6.0 in the lumen of these early endosomes, with a 
further reduction to pH 5 during progression from late endosomes to lysosomes (Khalil et 
al., 2006; Morille et al., 2008; Ziello et al., 2010; Xiang et al., 2012; Gasc n  et al., 2013; 
Xiang and Zhang, 2013).  
  
A common misconception has resulted in the clathrin-mediated endocytosis and receptor-
mediated endocytosis being deemed to be one and the same. As shown in Figure 1.9, 
clathrin-mediated endocytosis can occur in an adsorptive or receptor-mediated manner. 
Additionally, it has also been established that most of the pinocytic pathways, including 
CME involve receptor-ligand interactions. Commonly, in gene delivery, the clathrin-
mediated pathway is targeted by using certain ligands, which can specifically recognize 
certain receptors on the cell surface. This results in an increase in the internalization of 
the particles and offers the possibility of targeting specific cells that substantially over-
express certain receptors (Khalil et al., 2006; Xiang and Zhang, 2013). Use of receptor-
mediated endocytosis has been widely explored over the years, particularly for its role in 
liver-directed gene therapy. The ASGP receptor-mediated endocytosis has been exploited 
by coupling appropriate motifs, glycoproteins, lactose or galactose to delivery systems. 
While there are several ligands that have been investigated for cell selective transgene 
expression both in vivo and in vitro, galactose is possibly the most extensively studied 





1.4.1.2 Caveolae-mediated endocytosis  
 
Caveolae are small, hydrophobic membrane flask-shaped microdomains that are rich in 
cholesterol and sphingolipids. Classically, CvME occur in the wall lining of endothelial 
cells.  Caveolae are found in many different cell types, with diameter in the 50 – 100 nm 
size range (Ziello et al., 2010; Xiang et al., 2012).  
 
Caveolae-mediated endocytosis (CvME) is dynamin-dependent and receptor-mediated, 
and its role in DNA delivery was reported in the internalisation of cationic PEI 
polyplexes. This was observed to take place by both clathrin and caveolae-mediated 
mechanisms. An intriguing finding using inhibitor studies showed the caveolae-mediated 
route to have led to productive transfection. Larger particle sizes in the order of 500 nm 
are preferentially taken up via this route, while smaller particles may use clathrin-
mediated endocytosis (Zuhorn et al., 2007; Xiang et al., 2012). The high transfection 
efficiency could be attributed to lack of pH drop in this pathway. Studies have shown 
caveolae-internalised pathogens to be transported in the cytoplasm to other organelles 
thus avoiding lysosomal degradation. While it remains unlikely that they contribute 
significantly to constitutive endocytosis, caveolae-mediated endocytosis is still a 
promising strategy for gene delivery especially if the internalization can be increased, 
possibly through the use of specific receptors for caveolae (Khalil et al., 2006; Morille et 
al., 2008; Ziello et al., 2010; Xiang et al., 2012; Gasc n  et al., 2013; Xiang and Zhang, 
2013). 
 
1.5 Strategies in liver-directed gene delivery 
1.5.1 Overview 
 
The liver is the largest visceral organ in the body. It plays an integral and central role in 
many metabolic pathways such as in synthesis of proteins, posttranslational modifications 
as well as lipid synthesis. It is also associated with many genetically-based diseases such 
as haemophilia, lipoprotein receptor deficiency, cancer and life-threatening Hepatitis B.  
For this reason, the liver is considered one of the most important targets for gene therapy 




Liver cancer has been established as one of the most malignant cancers. Statistics have 
shown that it is fifth most frequent cancer in the world. However, this value rises to a 
third in developing countries among men after lung and stomach cancer.  Poor prognosis 
may also contribute to the high mortality associated with this cancer and makes it the 
third leading cause of cancer deaths globally (Ananthakrishnan et al., 2006; Wang et al., 
2009).  
 
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, often 
associated with Hepatitis B virus (HBV) and Hepatitis C (HCV) infections. Other risk 
factors include diabetes mellitus (DM), aflatoxin exposure, excessive alcohol intake, and 
tobacco use. Statistics have also shown that the highest HCC incidents are in China, 
Taiwan and sub-Saharan Africa. Interestingly, these regions are found to be endemic for 
HBV infections, aflatoxin exposure, alcohol intake and tobacco use (Ananthakrishnan et 
al., 2006; Datta, 2008; Wang et al., 2009). In a report by Hall et al. (2011), it was 
projected that Africa will have an estimated 23.9 million people living with DM by 2030.  
This undoubtedly bears significant implications for the currently high HCC prevalence. 
Coupled with high rates of communicable diseases such as HIV, malaria and tuberculosis 
in the region, morbidity and mortality will be consequentially impacted (Hall et al., 
2011). Development of new therapeutic modalities is hence very important for the future 
therapy of liver associated diseases.  
 
1.5.2 Asialoglycoprotein (ASGP) receptor-mediated delivery for 
hepatocyte-specific therapy 
 
One of the major challenges faced by many therapeutics in systemic gene delivery to the 
liver relates to traversing the vascular walls of hepatocytes (Kawakami et al., 2001; 
Higuchi et al., 2006). Figure 1.10 provides a diagrammatic representation of hepatocytes 





Figure 1.10 Diagrammatic representation of hepatocytes (Pathak et al., 2008) 
 
It is known to lack a basement membrane and rather possesses a fenestrated endothelium 
of 100 nm diameter pore size. Therefore, for efficient internalization, vector-cargo 
complexes should be small enough to pass through the fenestrae and enter into the space 
of Disse, which is in direct contact with hepatocytes (Higuchi et al., 2006; Pathak et al., 
2008; Mishra et al., 2013). Additionally, while many of these complexes are able to 
delivery genes to the liver, they often do not efficiently target the parenchymal hepatocyte 
(Ganem, 1999). One of the reasons relates to the three additional Gal/GalNac C-type 
lectin receptors viz. the Kupffer cell receptor, the macrophage galactose lectin and the 
scavenger C-type lectin. This may lead to the misdirection of vectors (Khorev et al., 
2010; Sonoke et al., 2011). 
 
The ASGP receptor is a high-capacity membrane-bound carbohydrate-binding protein 
located abundantly on parenchymal hepatocytes. ASGP receptors are calcium-dependent 
(C-type) lectins randomly located on the sinusoidal (basolateral) plasma membrane 
domain facing the capillaries. These receptors present in excess about 1 X 105 - 5 × 105   
binding sites per cell (Lee and Lee, 1987; Cristiano et al., 1993; Kawakami et al., 1998; 
Kawakami et al., 2001; Singh and Ariatti, 2003; Stokmaier et al., 2009; Xiao et al., 
2013). One of the important roles of the ASGP receptor is to maintain serum glycoprotein 
levels by processing and clearing desialylated glycopeptides and lipossacharides that 
contain terminal end galactose and N-acetylgalactosamine (GalNac) residues (Stokmaier 
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et al., 2009; D‟Souza et al., 2010; Christie et al., 2014). This activity of the ASGP 
receptor was initially described by Ashwell and colleagues who discovered the removal 
of diasialyated glycoproteins from the circulation and their subsequent degradation in the 
liver (Ashwell and Kawasaki, 1978; Ashwell and Harford, 1982; Bernades et al., 2010; 
Stokmaier, 2010). The X-ray crystal structure of the human ASGP receptor has been 
determined as shown in Figure 1.11 (Khorev, 2007; Khorev et al., 2008). 
 
 
Figure 1.11 X-ray structure of the ASGP receptor showing the active binding site located 
in the carbohydrate recognition domain (Khorev, 2007) 
 
It comprises 2 single-spanning membrane proteins, designated the H1 and H2 subunits in 
the ratio of 5:1. Both of these subunits are required for full functionality of the receptor. 
The carbohydrate recognition domain (CRD) is found on the major H1 subunit. The 
major subunit, H1, exclusively contains the signal for endocytosis by mediation of the 
Ca++-dependent recognition of D-galactose and N-acetyl-D-galactose (D-GalNac) 
resulting in displacement of two water molecules which co-ordinate this action in the 
absence of a cognate ligand. H2 contributes an important element to basolateral sorting of 
the hetero-oligomeric receptor molecules and thus, is more involved in the functional 
configuration (Khorev et al., 2008; Stokmaier et al., 2009; Bernardes et al., 2010). 
 
Evaluations were carried out on affinity of D-GalNac derivatives to the rat hepatocyte 
ASGP receptor.  The highest affinity reported was for the tri-galactosides, followed by bi-
galactosides and lastly, mono-galactosides. This phenomenon has been described as the 
“cluster effect”. And thus, modifications of liposomes by incorporating tri-galactoside 
ligands have resulted in increased recognition and avidity by these ligands for this 
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receptor (Kawakami, 2000; Singh and Ariatti, 2003; Khorev, 2007; Stokmaier et al., 
2009). Although triantennary ligands have displayed a higher affinity than the mono- and 
diantennary counterparts, some of the challenges they present include complexity in 
structure, and in upscaling to industrial production as well as possible antigenicity.  The 
reduced complexity with which monoantennary ligands can be synthesised still makes 
them the preferred choice in ASGP receptor-mediated delivery (Singh and Ariatti, 2003; 
Bernades et al., 2010; Stokmaier et al., 2009). Optimisation of these small mono-
antennary ligands by addition of small-molecule analogues can provide the potential to 
increase the relatively weak binding kinetics (Mamidyala et al., 2011; Maslov et al., 
2011).  
 
Acetylation, PEGylation, and glycosylation have been reported to be effective strategies 
towards improvement of transfection efficiency in dendrimers (Fant et al., 2010; Hu et 
al., 2011; Maslov et al., 2011). Glycosylation and PEGylation have been extensively 
explored in lipoplex formulations.  However, currently there is limited data available 
pertaining to modifications of mono-antennary ligands by acetylation, and how that 
impacts on their binding affinity to the ASGP receptor. Nevertheless, the exclusive 
expression of ASGP receptors by parenchymal hepatocytes coupled with high specificity 
and capacity for internalisation of cognate ligands make the ASGP receptor an attractive 
target in development of hepatocyte-specific therapeutics. It is imperative to investigate 
ways by which these can be modified for improved binding affinity to the receptor, which 
will essentially have an impact on transfection efficiency (Stokmaier et al., 2009; Khorev 
et al., 2010).  
 
1.6 Outline of thesis 
 
An introduction to gene therapy as an alternative therapeutic strategy for treatment of 
many diseases is presented in Chapter One. While many advances have been made, it is 
imperative that more robust efforts be focused on non-viral gene delivery systems. 
Cationic liposomes remain vectors of choice due to their many important attributes; 
however, it is pertinent that key mechanisms and challenges presented in gene delivery be 
addressed. In targeted delivery, the use of ligands becomes even more useful in order to 
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enhance cell-specificity. The effects of acetylation on galactose-derived (galactoside) 
ligands were investigated for in vitro and in silico. 
 
Thus the primary aims and objectives of this study as presented in Chapter Two were to: 
 
a) formulate cationic liposomes that exhibit dual-functionality in respect of targeting 
and long-circulation for liver-targeted delivery. Comparative analysis has thus been 
carried out for feasibility of targeting, where galactoside ligands viz. Sc6 and Sc9 have 
been formulated into liposomes and attached for recognition via the ASGP receptor. 
Additionally, effects of PEG have been investigated with some liposomes incorporating 
PEG in their formulations.  
b) carry out in vitro investigations to characterise morphological and  
physicochemical properties of the liposomes, the DNA-binding interactions, serum 
nuclease protection and cytotoxicity assays. 
 c) evaluate the in vitro transfection activity via  the ASGP receptor-mediated 
endocytosis in hepatocellular carcinoma cell line (HepG2).  This has been achieved by 
comparing transgene expression in the ASGP receptor-negative HEK293 and receptor-
positive HepG2 cell lines. Furthermore, receptor-mediated internalisation was verified by 
introducing a competitive inhibitor, asialofetuin and comparing the gene expression levels 
against the unsaturated receptor levels. 
d) assess in silico behaviour of binding affinities of galactose ligands by performing 
molecular modelling and docking studies using the Autodock Vina software programme. 
 
Findings from the study are presented in Chapter Three.  Discussions have centred around 
the various aspects critical for successful gene delivery as per the aims and objectives. 
Ultimately, transfection efficiencies for both ligand-derived lipoplexes were evaluated 
and comparative analysis was drawn between the derivatives. Additionally, calculated 
binding affinities of the ligands in question were discussed in terms of their avidity for the 
ASGP receptor. Chapter 4 provides overall conclusions drawn from the findings of the 





2 CHAPTER TWO: MATERIALS AND METHODS 
2.1 Materials 
 
The cationic lipid 3β[N-(N′ , N′ -dimethylaminopropane)-carbamoyl] cholesterol 
(Chol-T) was previously prepared in the Department of Biochemistry, University of 
KwaZulu-Natal (UKZN, Westville) according to the protocol of Gao and Huang (1991). 
Galactosides viz. 1) cholest-5-en-3-yl 2-[4-(β-D-galactopyranosyl-1-oxymethyl)-1H-
1,2,3-triazol-1-yl]ethylcarbamate (Sc6)  and 2) cholest-5-en-3-yl 2-[4-(2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl-1-oxymethyl)-1H-1,2,3-triazol-1-yl]ethylcarbamate (Sc9) 
were synthesised in the Department of Chemistry of the University of Witswatersrand 
(South Africa).  L-α-phosphatidylethanolamine dioleoyl (DOPE) was supplied by Sigma, 
St. Louis, MO, USA. 1,2-distearoyl-sn-glycerophosphoethanolamine-N-
[carboxy(polyethylene glycol) 2000] (ammonium salt) (DSPE-PEG2000)  was obtained 
from Avanti Polar Lipids, Alabaster, USA. 
 
2-[4-(2-hydoxyethyl)-1-piperazinyl] ethane sulphonic acid (HEPES) and the MTT salt (3-
(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide) were purchased from 
Merck, Damstadt, Germany. Ultrapure DNA grade agarose was purchased from Bio-Rad 
Laboratories, Richmond, USA. pCMV-luc DNA was purchased from Plasmid Factory, 
Bielefeld, Germany. HEK293 cells were supplied by the University of the Witwatersrand 
Medical School (South Africa) and HepG2 cells were obtained from Highveld 
Biologicals (Pty) Ltd. (Lyndhurst, South Africa).  Asialofetuin (Type I, from foetal calf 
serum), bicinchoninic acid (BCA) solution, copper (II) sulphate solution and the protein 
standard, bovine serum albumin (BSA) (1 mg BSA/ml in 0.15 M NaCl) were obtained 
from Sigma-Aldrich Inc., St, Louis, MO, USA.   Phosphate-buffered saline (PBS) tablets 
and trypsin-versene were purchased from Calbiochem, Canada and Lonza Biowhittaker, 
Walkersville, MD respectively.  
 
The cell culture lysis reagent (1 X) (25 mM Tris-phosphate, pH 7.8; 2 mM dithiothreitol; 
2 mM 1,2-diaminocyclohexane-N-N-Nʹ-Nʹ-tetra-acetic acid; 10 % (v/v) glycerol; 1 % 
(v/v) Triton X-100)  and luciferase assay reagent (20 mM tricine; 1.1 mM magnesium 
carbonate hydroxide, pentahydrate; 2.7 mM magnesium sulphate; 0.1 mM EDTA; 33.3 
mM dithiothreitol; 270 μM coenzyme A; 470 μM luciferin; 350 μM ATP) were 
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purchased from Promega Corporation, Madison, WI, USA. Penicillin/streptomycin 
mixture (10 000 U/ml penicillin, 10 000 μg/ml streptomycin) and fetal bovine serum 
(FBS) were purchased from Gibco InvitrogenTM, New Zealand. All tissue culture plastic 
consumables were purchased from Corning Incorporated, New York, USA. All other 
reagents were of analytical grade.  
 
2.2 Formulation of liposomes 
 
Six liposomal formulations were prepared using components as shown in Figure 2.1. 
Preparations was done in 1 ml of sterile HBS (20 mM HEPES, 150 mM NaCl, pH 7.5) at 
a total lipid concentration of 4 mM as per Table 3. 
   
   
Figure 2.1 Structures of components of liposomal formulations used in this study  
 
Table 2.1 Components of the liposomal formulations (µmole/ml) 
    Chol-T DOPE Sc6 Sc9 DSPE-PEG2000 
SM1 2 2 - - - 
SM1(+PEG) 2 1.8 - - 0.2 
SM2 2 1.6 0.4 - - 
SM2(+PEG) 2 1.6 0.4 - 0.2 
SM3 2 1.6 - 0.4 - 
SM3(+PEG) 
 





Untargeted and unPEGylated control (SM1) comprised of equimolar quantities of Chol-T 
and DOPE. The PEGylated control contained DSPE-PEG2000 at 0.2 µmole/ml equivalent 
to 5% mole ratio. Targeted liposomes contained varying amounts of Chol-T, DOPE and 
respective galactosides viz. Sc6 (SM2 and its PEGylated derivative) and Sc9 (SM3 and its 
PEGylated derivative). The PEGylated formulations all contained DSPE-PEG2000 at 5% 
mole ratios. 
 
The following mixtures: viz. SM1; SM1(+PEG); SM2 and SM2(+PEG) were dissolved in 
1 ml of dry chloroform, while SM3 and SM3(+PEG) mixtures were dissolved in 1 ml of 
chloroform:methanol (50:50 v/v) mixture. The lipid components were deposited as a thin 
film in a test tube by rotary evaporation of the solvent in vacuo at 25 °C. Thereafter, the 
film was hydrated at 4 °C for 24 h and the resulting mixture was vortexed. The 
suspension was then sonicated in an Elma Transsonic bath type sonicator (T 460/H) for 5 
min to obtain unilamellarity as determined by transmission electron microscopy (TEM). 
Liposomes were routinely stored at 4 °C until use. 
 
2.2.1 Preparation of cationic cholesterol derivative 3 _ [N-(N’, N’-dimethyl-
aminopropane)-carbamoyl] cholesterol (Chol-T) 
  
The synthesis steps of the Chol-T were carried out as follows: 3-
dimethylaminopropylamine was added to a solution of cholesteryl chloroformate in 
dichloromethane. This synthesis reaction proceeded for an 1 hour at room temperature 
(Figure 2.2) and monitored by TLC (results not shown). The solvent (dichloromethane 
and excess 3-dimethylaminopropylamine) was subsequently removed by rotary 
evaporation in a Büchii Rotavapor-R. The residue resulting from the evaporation was 
dissolved in absolute ethanol and allowed to crystallise overnight at -4 ºC. The product 
was then recrystallised, filtered under a stream of dry nitrogen gas and further dried by 





Figure 2.2 Synthesis reaction scheme of cationic cholesterol derivative Chol-T (T) from 
starting material cholesteryl chloroformate (C)  
 
2.3 Formulation of lipoplexes 
2.3.1 Plasmid amplification and isolation 
 
pCMV-luc DNA (1 µg) was added to competent cells (200 µl) and allowed to stand on 
ice for 30 minutes. The cells were subjected to heat-shock at 42 °C for 90 seconds and, 
thereafter, placed on ice for 2 minutes. Cells were then introduced into 250 ml sterile LB 
broth (containing 2.50 g tryptone, 1.25 g yeast extract powder, 1.25 g NaCl, and 10 μg/ml 
ampicillin). These were maintained in a shaking incubator at 37 °C for 36 hours, in order 
to select transformants. The pCMV-luc DNA was then isolated according to the protocol 
outlined in the Promega Technical Manual no. 033 for pGL3 Luciferase Reporter 
Vectors. Purity and amount of plasmid DNA isolated was determined using a 
ThermoScientific NanoDrop 2000c spectrophotometer (Wilmington, USA). The isolated 
DNA was diluted to a concentration of 0.5 µg/µl with 18 MOhm water, and stored in 
aliquots of 200 µl, at – 20 °C. For verification of the plasmid, the isolate (0.5 µg) and 
pCMV-luc stock (0.5 µg), each in 10 µl HEPES buffered saline (HBS) were mixed with 
gel loading buffer (2 µl) and subjected to electrophoresis for 60 minutes at 50 V on 1 % 
agarose gel in a buffer comprising 36 mM Tris–HCl, 30 mM sodium phosphate and 10 





2.3.2 Formation of lipoplexes 
 
Lipoplex formation was achieved by the addition of the isolated pCMV-luc DNA (0.5 µg) 
to increasing amounts of PEGylated and unPEGylated liposome suspensions resulting in 
different liposome (+) / DNA (˗) ratios (Figure 2.3). 
 
Figure 2.3 Diagrammatic representation showing formulation of the various lipoplexes 
(adapted from Podesta and Kostarelos, 2009) 
 
The added pCMV-luc DNA and liposomal suspension volume was brought to a final 
volume of 10 µl with HBS. The liposome (+) / pDNA (˗) charge ratios ranged from 0.5/ 1 
to 6/1. Lipoplexes were then incubated at room temperature for 20 min prior to use. 
Lipoplexes were used within one hour of preparation time. 
 
2.4 Gel retardation assay 
 
Lipoplexes were prepared as described above to achieve (+) liposome / (˗) DNA charge 
ratios in the range 0.5:1 to 6:1. After 20 mins of incubation, 2 µl of the gel loading buffer 
(0.05% bromophenol blue, 40% sucrose) was added to the complexes. The samples were 
then subjected to electrophoresis (50 V) on a 1% agarose gel containing ethidium 
bromide (EtBr) (1.5 µg/ml) in a 1x electrophoresis buffer comprising 36 mM Tris–HCl, 
30 mM sodium phosphate and 10 mM EDTA (pH 7.5) for 90 min. Viewing of the gels 
was carried out in a Vacutec Syngene G:box gel documentation system (Syngene, 













2.5 Serum nuclease digestion assay 
 
The complexes containing 0.5 µg pCMV-luc DNA at sub-optimal, optimal and super-
optimal retardation ratios as determined from the gel retardation assay (section 2.4), were 
incubated in HBS for 20 min at room temperature. Foetal bovine serum (FBS) was added 
to a final concentration of 10% (v/v) and samples were incubated for 4 h at 37 °C. 
Thereafter, EDTA and SDS were added to final concentrations of 10 mM and 0.5% (w/v), 
respectively and complexes incubated for a further 20 min at 55 °C. Thereafter, 
approximately 2 µl of the gel loading buffer (0.05% bromophenol blue, 40% sucrose) was 
added to the suspension. Electrophoresis was carried out at 50 V on a 1% agarose gel 
containing ethidium bromide (1.5 µg/ml) in a buffer comprising 36 mM Tris–HCl, 30 
mM sodium phosphate and 10 mM EDTA (pH 7.5) for 90 min. Gels were viewed as 
described in section 2.4. 
 
2.6 Ethidium bromide intercalation assay 
 
Approximately, 2 µl of ethidium bromide (EtBr) solution (100 µg/ml) was added to 100 
µl of HBS in wells of a black 96-well microtitre plate. Fluorescence was measured at an 
emission wavelength of 580 nm and an excitation wavelength of 525 nm in a Glomax 
multi-detector system (Promega Biosystems, Sunnyvale, USA). This initial reading was 
set as 0% relative fluorescence. The next reading was taken after addition of 2.4 µl (1.2 
µg) of pCMV-luc DNA to the sample and set as 100% relative fluorescence. Thereafter, 
cationic liposome suspensions (1 µl) were added stepwise to the pDNA-EtBr solution. 
The fluorescence intensity was recorded after every liposomal addition, until a plateau in 
the readings was observed. Results were presented as relative fluorescence versus 
liposome concentration. 
 
2.7 Cryo-transmission electron microscopy 
 
Liposome and lipoplex suspensions were diluted 1:5 with sterile HBS. Approximately 2 
µl, of liposome/lipoplex suspension was then deposited on a carbon coated 400-mesh 
copper grid. To this was added 2 µl of 1% (w/v) uranyl acetate and the grid was allowed 
to dry for 2 min. Excess suspension was removed using filter paper and the grid was 
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placed under liquid nitrogen. Grids were then immediately transferred into a GATAN 
cryo-holder maintained at ˗170 °C, and thereafter introduced into the microscope for 
observation at ˗150 °C. Images were obtained under cryogenic conditions at 100 kV using 
a JEOL JEM1010 electron microscope (Tokyo, Japan). The micrographs were generated 
by a MegaView III camera and SIS i-TEM software facilitated measurements of 
liposomes on calibrated images. 
 
2.8 Size and zeta potential measurements 
 
Size distribution patterns and zeta potentials were measured by dynamic light scattering 
(DLS) using a Malvern Zetasizer Nano-ZS instrument (Malvern Instruments Ltd., 
Worcestershire, UK.) operating at 25 °C. Liposome suspensions were prepared by 
addition of 10 µl of liposome suspension to 990 µl HBS. Lipoplexes were formed by 
complexing 10 µl of liposome suspension with corresponding amount of DNA to obtain 
optimal end-point ratios. The final volume was made up to 1 ml. The 1 ml suspensions 
were added to the appropriate cells and thereafter, readings were taken. A DTS0012 
polystyrene disposable sizing cuvette for the Z-average diameter measurements and a 
DTS-1061electrocell for the zeta potential measurements were used. All measurements 
were done in triplicate. 
 
2.9 Cell culture and maintenance 
 
HEK293 and HepG2 cells were maintained in 25 cm2 flasks containing EMEM and 
placed in a Steri-cult CO2 incubator HEPA Class 100 (Thermo-Electron Corporation, 
Waltham, Massachusetts, USA) at 37 °C under 5% CO2. Cell culture medium was 
supplemented with 10% (v/v) FBS, penicillin (100 units/ml), streptomycin (100 µg/ml), 
and L-glutamine (4 mM) (Gibco BRL Life Technologies). Cells were split 1:3 every 4–5 






2.10 MTT cell viability assay 
 
Both cell lines were seeded at a density of 2.5 × 104 cells per well in a 48-well microtitre 
plates in complete medium (EMEM, 10% FBS, streptomycin (100 µg/ml), and penicillin 
(100 U/ml)) and incubated at 37 °C in a humidified atmosphere with 5% CO2 for 24 h. 
Thereafter, the medium was discarded and fresh complete medium (0.3 ml) was added to 
the wells.  The lipoplexes were prepared in triplicate at the sub-optimal, optimal and 
super-optimal ratios as in section 2.5, and added to the cells.  Cells not treated with the 
lipoplexes were set up as controls (100%). Incubation of the cells was carried out for a 
further 48 h at 37 °C. Thereafter the spent medium was removed, and cells rinsed with 
PBS, followed by addition of 0.2 ml of EMEM and 0.2 ml 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide solution (MTT). The cells were incubated for an 
additional 4 h at 37 °C. Thereafter, the MTT-containing medium was removed from the 
wells, and 0.2 ml of dimethylsulphoxide (DMSO) was added to dissolve the formazan 
crystals produced by the cells. The absorbance was measured at 570 nm using a Mindray 
MR-96A micro plate reader (Vacutec, Hamburg, Germany). Cell viability was 
determined as the percentage fluorescence relative to the untreated control (100%). The 
results were calculated and expressed as the mean ± standard deviation. Experiments 
were performed in triplicate.  
 
2.11 Transgene expression and Protein Determination Assays 
2.11.1 Transfection assay in HEK293 and HepG2 cell lines 
 
HEK293 and HepG2 cells were seeded in a 48-well plate at a density of 2.5 × 104 cells 
per well in 0.3 ml complete medium.  Thereafter, the medium was discarded, and wells 
were rinsed with PBS, being careful not to dislodge the cells. The lipoplexes were 
prepared as in section 2.5 and added to a set of triplicate wells for each ratio. Two 
controls, one containing only cells and the other containing cells with naked DNA were 
also set up. Following lipoplex addition, the plate was incubated for a further 48 h at 37 
°C. Thereafter, the medium was removed and cells washed twice with PBS, being careful 
not to dislodge the cells. This was then followed by the determination of luciferase gene 




2.11.2 Competitive inhibition assay in the HepG2 cell line 
 
HepG2 cells were seeded in a 48-well plate at a density of 2.5 × 104 cells per well in 0.3 
ml complete medium. Thereafter the medium was removed and cells replenished with 
fresh medium.  The lipoplexes were prepared to sub-optimal, optimal and super-optimal 
ratios as in section 2.5. Free asialofetuin (final concentration 200 µM) was introduced to 
the cells 20 min prior to the addition of the lipoplexes. After lipoplex addition, the plate 
was incubated for a further 48 h at 37 °C. This was followed by the Luciferase assay for 
gene expression. 
 
2.11.3 The luciferase assay 
 
The Luciferase Assay was carried out as per protocol set out by Promega. Briefly, after 
washing of cells with PBS, 100 µl of freshly prepared of cell culture lysis buffer (25 mM 
Tris–phosphate, pH 7.8, 2 mM dithiothreitol, 2 mM 1,2-diaminocyclohexane-N,N,N‟,N‟-
tetraacetic acid, 10 % v/v glycerol, 1 % v/v Triton X-100) (Promega) was dispensed into 
each well and the plate was gently rocked on a STR 6 (Stuart Scientific, Staffordshire, 
UK) platform rocker at 30 rpm for 15 minutes. Lysates were then transferred into 
microcentrifuge tubes and spun at 13 000 rpm in Eppendorf microcentrifuge for 30 secs. 
The level of luciferase gene expression was measured by adding 50 µl of luciferase 
reagent (Promega) to 20 µl of lysate or supernatant. Luminescence was measured using a 
Glomax Multi+ Detector system. Thereafter, protein content in the supernatant was 
determined using the BCA Protein Assay reagent (Sigma) with bovine serum albumin as 
the standard. The expression data are expressed as relative light units (RLU) per mg of 
total soluble cell protein. Two controls were employed i.e. C(-): untreated cells, C(+): 
cells with uncomplexed free DNA. All experiments were carried out in triplicate.  
 
2.11.4 The bicinchoninic acid (BCA) assay 
 
Protein determination was carried out using the BCA assay. In order to construct a protein 
standard curve, standard BSA solutions (ranging from 0 to 30 μg/50 μl in increments of 5 
μg/50 μl) were prepared in a final volume of 50 μl with 18 MOhm water. These were 
mixed with 1 ml BCA working reagent (BCA solution:copper (II) sulfate solution, 50:1 
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v/v) and maintained at 37 °C for 30 minutes. Solutions were cooled to room temperature 
and absorbances read at 540 nm in a Mindray MR-96A microplate reader. The cell free 
extracts (50 μl) were mixed with BCA working reagent (1 ml) and treated in the same 
way as the standards. The soluble protein content of the extracts was obtained by 
extrapolation from the standard curve. 
 
2.12 Statistical analysis 
 
Statistical analyses were performed using ANOVA (one-way analysis of variance) 
followed by Tukey Multiple Comparison‟s Test to compare between groups. P values less 
than 0.05 were regarded as significant. 
 
2.13 Docking studies 
 
Docking studies were performed at Discipline of Pharmaceutical Chemistry, UKZN. 
Molecular flexible docking studies were performed using the AutoDock Vina and 
AutoDock graphical user interface (GUI). All non-standard amino acid residues were 
deleted. The crystal structure of the 3D ASGP receptor structure for carbohydrate-binding 
domain was downloaded from Protein Data Bank (Code IDV8, 2.3 Å resolution). All the 
crystallographic water molecules, other than the molecules forming coordinate bonds 
with Ca++ ions within the binding sites, were removed. The bond orders and hydrogen 
atoms were assigned to define the correct ionization states. Optimized metal binding 
states were generated within pH 7.0± 4.0. An H-bond assignment was given to orient the 
water molecules to optimize H-bonding. Positional constraints were added to replace the 
oxygen atom of the Ca-coordinated water molecules as coordinate bonding of the ligand 





3 CHAPTER THREE: RESULTS AND DISCUSSION 
3.1 Physicochemical characterisation of liposomes 
 
It is important to assess and analyse morphological characteristics of liposomes as they 
relate to functionality of the liposome-DNA complexes. Commonly investigated features 
include liposome size, surface charge, shape and lamellarity (Patil and Yadhav, 2014).  
 
3.1.1 Preparation of liposomes 
3.1.1.1 Components of liposomes viz. Chol-T, DOPE and PEG 
 
All six liposomal formulations viz. SM1, SM2, SM3 and their PEGylated derivatives 
were visually observed to be stable for several months when stored at 4 °C. They 
comprised Chol-T and DOPE at varying molar ratios. Incorporating Chol-T in this study 
is a direct result of literature citings showing improved transfection by cholesterol-based 
lipids. Daniels et al. (2011) carried out a comparative analysis of use of Chol-T and Chol-
Q as cationic cholesteryl moieties. Chol-T features a dimethylamino head group, and 
similar transfection agents including DC-Chol have been designed and reported to be 
efficient in transfection (Singh and Ariatti, 2006). DC-Chol represents the first 
cholesterol-based cationic lipids to be used in clinical trials owing to its low cytotoxicty 
(Battacharya and Bajaj, 2009). Chol-T was observed to result in the highest transfection 
efficiency, a threefold increase over Chol-Q, which has a trimethyl ammonium head 
group. The increase was attributed to promotion of endosomal escape of the DNA cargo. 
An important attribute of carbamate-linked lipids is the facilitated disconnection of 
hydrophobic and hydrophilic portions of the lipoplex as a result of the low pH in early 
endosomes. This in turn leads to DNA release (Balram et al., 2009; Daniels et al., 2011).  
 
The hydrophobic cholesterol moiety not only enhances rigidity and thereby retention of 
the liposomal cargo, but also improves the stability of the liposomal bilayer. Additionally, 
there is protection of the liposomal membrane against dissociation by plasma proteins. 
These attributes are due to high gel-to-liquid crystalline phase Tm of about 55 °C – 58 °C 
which prevents coexistence of two phases at physiological temperature of 37 °C (Perche 
and Torchillin, 2013). Perhaps the most important reason relates to the ability of 
cholesterol to promote HII phase organisation; a critical factor in endosomal escape. This 
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important trait is further exploited in the use of cholesterol in combination with a 
zwitterionic or neutral co-lipid, such as the fusogenic DOPE or DOPC. A study by Yang 
et al. (2013) investigating cholesterol content in DC-Chol/DOPE lipoplexes revealed that 
an increase in cholesterol content led to increased transfection activity. This was thought 
to be due to more stable liposomes with lower cytotoxicity profile and therefore higher 
transfection activity. It has been suggested that DOPE facilitates formation of lipid 
bilayers of cationic cholesteryl cytofectins. An important difference is that DOPC, unlike 
DOPE induces the lamellar phase in lipoplexes. DOPE however, was found to be more 
useful in its effect on transfection owing to its ability to induce inverted hexagonal phase.  
Study results showed that DOPE led to 70% better transfection than in complexes with 
same amount of DOPC. Another study demonstrated superior transfection results of 
DOPE when compared to the lamellar phase forming DPPE (Balram et al., 2009; 
Ramezani et al., 2009; Madeira et al., 2011; Pisani et al., 2011). 
 
Investigations by Moghaddam and colleagues on lipoplex characteristics involving 
DOPE, DSPE, DOTAP and DSTAP revealed that the DSPE:DSTAP formulation was not 
possible.  However, by introducing double bonds in the lipid tail through substitution of 
DSPE with DOPE or DSTAP with DOTAP in a DSPE:DSTAP lipid combination 
mixture, a less compact lipid system resulted. This system provided for better hydration 
and dispersion in water resulting in different structures such as micelles, inverted micelles 
and hexagonal or lamellar phases (Moghaddam et al., 2011). By combining Chol-T and 
DOPE in a liposomal formula, it is expected that there would be increased transfection 
due to efficient endosomal escape of DNA. These results have been reported by Daniels 
et al., (2011) who confirmed better transfection and additionally, reduced cytotoxicity of 
these liposomes. 
 
Cationic liposomes, by virtue of their positive charge are prone to interactions with serum 
components which can lead to aggregrated complexes. This may result in various 
morphological changes in size, charge and behaviour of lipoplexes. Charge neutralisation 
can result from the positively charged serum proteins coating the surface of the 
lipoplexes. This forms a corona, which creates a sticky adhesion resulting in vesicles 
aggregating. Additionally, the weakened repulsions due to neutralised surface charge can 
lead to the particles sticking together (Yang et al., 2013). Aggregation and fusion not only 
impact on size, but also on the shelf life of liposomes. Electrostatic stabilisation can be 
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achieved by adjusting ionic strength or pH. This however, means that there is a degree of 
sensitivity related to changes in these parameters (Pannier et al., 2008; Yadav et al., 
2011). PEG formulations have been associated with increased stability, increased DNA 
protection, reduced surface charge, and reduced cytotoxicity. PEG-liposomes are highly 
stable dispersions which display enhanced transfection potential (Pannier et al., 2008; 
Tros de Illarduya et al., 2010). For this reason, comparative analysis of PEG effects on 
liposomes was done, where PEG-modification was achieved by introducing 5 % molar 
ratio of DSPE-PEG2000 . 
 
Liposomes composed of cholesterol and phospholipids are impacted by the amount of 
grafted PEG and length/molecular weight of the polymer. Long-chained and higher 
molecular weight DSPE-PEG2000 and DSPE-PEG5000 have been reported to produce better 
results than shorter chained PEG750 and PEG120. Managit et al., 2003 demonstrated that 
PEG2000 displayed a markedly higher longevity blood circulation than PEG350 to PEG750. 
PEG2000-Gal liposomes were eliminated at a slower rate. PEG2000 has been shown to be 
the best compromise in respect of molecular weight and was therefore chosen for this 
study. The quantity of PEG to be incorporated is another important factor to take into 
account.  PEG concentrations of up to 6 mol % were found to shield surface charge 
moderately, but at higher concentrations of 15% mole ratio, PEG completely abolished 
the effect of the charged groups. This becomes critical for cationic lipid-mediated 
delivery, which relies on the positive charge. Surface modification with 5.7% mol PEG 
was shown to improve ODN loading where structural stability of the resulting lipoplexes 
comprising cationic lipid DOTPA, DOGS, DDAB; helper lipid DOPE and PEG were not 
lost, while size was affected due to aggregation (Campbell et al., 2002; Immordimo et al., 
2006). Kibria et al., (2011) have also reported on use of 5 mol% DSPE-PEG2000 while 
Dadashzadeh et al. (2010) used 6.25 mol%. Hence in this study, we opted to use 5% mole 
ratio PEG which has been shown to reduce clearance while the cationic charge of the 
liposomes would still be retained (Perche and Torchillin, 2013). 
 
3.1.1.2 Targeting ligands 
 
Use of sugar-based cationic cholesterol derivatives has been extensively investigated for 
their ability to increase transfection in hepatocytes (Kawakami, 2000). The galactoside 
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cholesterol derivative ligand Sc9 was previously synthesized (Department of Chemistry, 
University of the Witwatersrand) by a copper-mediated „click‟ reaction between the 2-
propynylcarbamate derivative of cholesterol and O-tetraacetate galactose azide (Hean et 
al., 2010). In an additional deacetylation step, the galactoside viz. Sc6, was formed 
(Figure 3.1).  
 
Figure 3.1 Click chemistry galactosides viz. Sc6 and Sc9 
 
Click chemistry has emerged as an important tool when preparing structurally diverse 
glycoconjugates for biomedical purposes. This relates to its numerous advantages such as 
shorter synthetic sequences, higher cyclisation yields and ease in resolving anomeric 
mixtures thus allowing for preparation of well-defined analogues (Wilkinson et al., 2009). 
Synthesis of the galactoside derivative, Sc9 using „click chemistry‟ was found to be 
desirable owing to its simplicity, and it allows for easier scale-up preparation of the 
galactosides (Wilkinson et al., 2009; Hean et al., 2010). Additionally, Sc9 has been 
incorporated in liposomal formulations for improved efficiency to the liver. The 
lipoplexes were examined for their ability to deliver siRNA for inhibition of hepatitis B 
virus replication. They were reported to be useful vectors, displaying minimal 
cytotoxicity and immunostimulatory effects, even at high siRNA concentrations (Hean et 
al., 2010).  
 
The galactosides, Sc6 and Sc9 were successfully incorporated into the liposomal 
formulations SM2 and SM3 (and their PEGylated derivatives), respectively. Comparative 




liposomes, with particular focus on their respective affinity for the ASGP receptor and 
transfection efficiency for liver-targeted delivery. 
 
3.1.1.3 Preparation method 
 
Formulation procedure and components impact the physical nature of lipoplexes (Ferrari 
et al., 2002). Unilamellar liposomes can be produced by various methods including the 
classical thin film hydration (Levine et al., 2013). Thin film hydration method was used 
to prepare the liposomal dispersion in this study. This technique requires that lipids be 
dissolved in organic solvents, usually chloroform or chloroforom:methanol mixtures (Dua 
et al., 2012). Following evaporation of the solvent, thin lipid films are hydrated by adding 
an aqueous medium such as HBS. Clear and stable MLV suspension were observed, 
which could be of heterogenous size and lamellarity (Patil and Jadhav, 2014).  
 
Reduction in liposome size presents an important aspect in liposomal preparation, as it 
increases cellular uptake where the physiological barriers in vivo can be overcome 
(Malaekeh-Nikouei et al., 2009). Whereas other methods are also known to reduce size 
such as French press and membrane extrusion, ultrasonic waves using a bath sonicator 
result in SUVs of satisfactory sizes. As expected, the suspension resulting from sonication 
was observed to be opalescent to clear and transparent. It is thus assumed that SUV of 
similar properties were produced; however, it is possible to have variations in size and 
size distributions between batches due to the fact that conditions of sonication are not 
always reproducible (Dua et al., 2012; Laouini et al., 2012; Akbarzadeh et al., 2013; Patil 
and Jadhav, 2014).  
 
3.1.2 Cryo-TEM images of liposomes 
 
Cryo-TEM allows for visualisation of liposomal morphology, lamellarity and 
importantly, it provides for quick estimation of size of individual liposomes (Smith et al., 
1997; Patil and Jadhav, 2014).  All liposomal samples appeared to be unilamellar, and 
were observed to be predominantly spherical and distinct vesicles as observed in Figure 
3.2. Studies on galactosylated cholesterol derivatised liposomes have shown similar 




Figure 3.2 Cryo-TEM images of liposomes showing distinct, spherical vesicles and 









The vesicle sizes for the untargeted SM1 were reported to have a mean diameter of 110 
nm. Similarly, Dorosamy et al. (2012) reported untargeted Chol-T:DOPE vesicle size 
diameters in the 80 – 100 nm range while inclusion of Chol-β-Gal resulted in 30 – 80 nm 
size diameters. Addition of targeting moieities to the liposomal formations of SM2 and 
SM3 led to mean size diameters of 235 nm while the PEGylated derivatives measured had  
mean diameters ranging from 35 – 126 nm. 
 
While cryo-TEM provided an estimation of sizes, these results cannot be conclusively 
taken to be representative of the liposomal populations in a sample. This is because most 
of the liposomes exist as a non-homogenous population. Sample preparations in TEM are 
generally complicated and can result in size and shape distortions. Cryo-TEM remains 
preferable to other microscopic techniques as it provides some morphological view; 
however, information gathered from this technique should ideally be used in conjuction 
with other techniques such as DLS (Laouini et al., 2012). From these results, it could be 
concluded that SUVs were successfully prepared as discernible vesicles with mean sizes 
ranging between 35 nm and 235 nm. 
 
3.1.3 Size and zeta potential measurements 
 
Dynamic light scattering techniques have been employed for quick estimation of size, 
measurements and distribution of liposomal formulations. Other colloidal properties are 
also assessed using this technique. Zeta potential (ζ-potential) studies allow for the 
estimation in how the negatively charged nucleic acids interact with the positive charges 
of the cationic liposome (Tros de Ilarduya et al., 2010; Patil and Jadhav, 2014). 
 
All formulated liposomes were found to be below 150 nm in size (Table 3.1). This is a 
particularly desirable as smaller particles with size range of 50 – 300 nm are expected to 
display significantly longer circulation time due to reduced RES uptake and reduced 







Table 3.1 Size distribution and zeta potential measurements for the liposomes using DLS 
 Size diameter (nm) PDI value ζ-potential (mV) 
SM1 125.00±0.44 0.208 +13.53 
SM1 (+ PEG) 88.07±0.76 0.225 ˗1.92 
SM2 121.10±1.91 0.212 +2.36 
SM2 (+ PEG) 81.57±0.33 0.202 ˗4.97 
SM3 140.27±0.06 0.228 +14.27 
SM3 (+ PEG) 129.57±2.35 0.309 ˗2.21 
 
No significant size difference was noted between the non-targeted control SM1 and the 
targeted SM2. As expected, PEG introduction resulted in clear compaction of sizes to ~80 
nm for derivatives SM1(+PEG) and deacetylated SM2(+PEG). Daniels et al., (2011) also 
reported stable PEGylated liposomes which were found to be in the 40 – 100 nm size 
range. Reduction in particle size diameter is attributed to the steric stabilisation through 
strong inter-membrane repulsive forces. The reduced Van der Waals forces between 
particles signify a lower tendency towards aggregation or fusion thus preventing 
formation of larger vesicles.  
 
Similar observations by Nie et al. (2012) confirmed that incorporation of 5 mol% PEG 
resulted in a narrower size distribution than the conventional unPEGylated derivatives. 
Interestingly, liposomal formulations SM3 and its PEGylated derivative which comprised 
acetyl groups presented larger mean diameters of 140.27 nm and 129.57 nm, respectively. 
This was found to be larger than the liposomes containing the conventional D-
galactopyranosyl group. This might be explained to structural dimensions where the 
acetyl groups possibly occupy more space due to the protruding methyl groups. Thus a 
bulkier configuration is most likely with SM3 and its PEGylated derivative SM3(+PEG) 




The polydispersity index (PDI) provides a means to monitor the relative width of 
liposomal size distributions (Levine et al., 2013). PDI values ranging between 0.1 and 0.2 
are indicative of narrow particle size distributions (Li et al., 2011). And if these values are 
in excess of 0.25, the particle sizes are said to be distributed over a broad range. All 
liposomes displayed PDI values which were less than 0.25 (Table 3.1). However, the 
acetylated SM3(+PEG) had PDI of 0.309 which suggests existence of particle sizes which 
fall out of the given range. Thus, for most of the liposomes, size distribution was mainly 
monodispersed and homogenous around the z-average diameter given. SUVs are 
however, inherently unstable and will therefore tend to fuse thereby forming larger 
vesicles therefore it is not uncommon to have heterogeneity where there might be a small 
population present made up of larger sized vesicles (Patil and Jadhav, 2014).  
 
ζ-potential is an important parameter used to characterise the surface of charged colloidal 
systems. It represents the electric potential in the interfacial double layer of nanoparticles. 
Measurements are based on particle electrophoretic mobility, which is converted to ζ-
potential using Smoluchowski or Huckel theory (Salopek et al., 1992; Laouini et al., 
2012; Honary and Zahir, 2013). The existence of positive charge is an important 
requirement in pDNA-cationic liposomes condensation (Ramezani et al., 2009).  
 
The untargeted control SM1 preparation exhibited an overall positive charge of +13.53 
mV. The cholesteryl galactoside targeting moieties by galactoside cholesterol Sc6 (in 
SM2) snd Sc9 (in SM3) had varying effects on the surface charge. SM2 liposome 
displayed a near neutral surface charge of +2.36 mV, while the acetylated SM3 liposome 
retained a positive charge of +14.27 mV. This could play an important role in how they 
interact with the negatively charged DNA, where SM3 would be expected to condense it 
more efficiently. The absolute value of surface charges of PEGylated derivatives viz. 
SM1(+PEG), SM2(+PEG) and SM3(+PEG) was reduced upon DSPE-PEG2000 inclusion. 
Reduction resulted in near-neutral charges at ˗1.92, ˗4.97 and ˗2.21 mVs, respectively. 
This can be explained in the context of PEG shielding effect where the hydrophilic 
polymer acts by masking of the surface charge and lowering electrophoretic mobility of 
the particles (Campbell et al., 2002; Nie et al., 2012). The surface charge of the near-
neutral SM2 was not significantly reduced upon PEG inclusion, which was consistent 
with results by Nie et al. (2012). While it is true that conventional liposomes with neutral 
charge are unstable and aggregrate, this is not likely to occur in this case as steric-
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repulsive propensity is conferred by the PEG polymer (Xiang and Zhang, 2013). In fact, 
neutrally charged PEGylated doxorubicin liposomes were shown to exhibit increased 
therapeutic activity, unaffected by their charge (Perche and Torchillin, 2013). 
 
3.2 Liposome-DNA interactions 
3.2.1 Gel retardation assay 
 
The gel retardation assay is commonly used to study the pDNA binding affinity of 
cationic liposomes. The formation of lipoplexes is due to strong electrostatic interactions 
between the cationic charges from lipids and the anionic DNA. The principle is thus 
based on the electrophoretic migration of the negatively charged pDNA to the positive 
anode in an electric field unless it is retarded or fully bound by the liposome to form large 
complexes possessing an electroneutral charge (Li et al., 2011). By determining the least 
amount of liposome required to bind all pDNA, optimal binding ratios can be obtained. 
 
In lanes 1 of each gel (Figures 3.3 and 3.4), three conformations of uncomplexed pDNA 
are visible, namely the superhelical, closed circular and linear. From lanes 2 to 8, 
increasing amounts of liposomes were added resulting in DNA becoming liposome-
bound.  This is also observed as a reduction in band intensity because of reduced amounts 
of DNA migrating into the gel. 
 
The untargeted control liposomes (SM1) were shown to fully bind the pDNA at a N:P 
ratio of 2.5:1. This end-point ratio possibly represents an N:P ratio where the liposome 
cationic charge is fully neutralised by the negatively charged phosphate groups of DNA. 
No further migration of free pDNA was observed in subsequent lanes, suggesting that the 
DNA was indeed fully-bound. The resulting lipoplexes could also be large and unable to 
diffuse through the agarose matrix as reported by Li et al., (2011). The PEGylated 
derivative SM1(+PEG) was observed to bind at a higher end-point ratio of 3:1. Inclusion 
of the galactosides viz. Sc6 and Sc9 in SM2 and SM3, respectively did not alter the 
optimal N:P binding ratios when compared to the untargeted SM1. These were 






   
 
Figure 3.3 Gel retardation assays showing optimal binding ratios for A) SM1 where lanes 
2 – 8 corresponded to N:P ratios 0.5:1, 1:1, 1.5:1, 2:1, 2.5:1, 3:1 and 3.5:1, respectively; 
and B) SM1(+PEG) where lanes 2 – 8 corresponded to N:P ratios 1:1, 2:1, 3:1, 4:1, 5:1, 




Figure 3.4 Gel retardation assays showing optimal binding for A) SM2 where lanes 2 – 8 
corresponded to N:P ratios 0.5:1, 1:1, 1.5:1, 2:1, 2.5:1, 3:1 and 3.5:1, respectively; B) 
SM2(PEG) where  2 – 8 corresponded to N:P ratios 1:1, 2:1, 3:1, 4:1, 5:1, 6:1 and 7:1, 
respectively; C) SM3 where lanes 2 – 8 corresponded to N:P ratios 0.5:1, 1:1, 1.5:1, 2:1, 
2.5:1, 3:1 and 3.5:1, respectively; and D) SM3(+PEG) where lanes 2 – 8 corresponded to 
N:P ratios 0.5:1, 1:1, 1.5:1, 2:1, 2.5:1, 3:1 and 3.5:1, respectively. 
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Table 3.2 Binding optimal N:P ratios and their corresponding N:P weight ratios  
 Optimal N:P 
charge ratio (+/˗) 
Optimal N:P 
weight ratio (w/w) 
SM1 2.5:1 4.41:1 
SM1(+PEG) 3:1 5.84:1 
SM2 2.5:1 4.39:1 
SM2(+PEG) 3:1 6.45:1 
SM3 2.5:1 4.49:1 
SM3(+PEG) 2.5:1 5.47:1 
 
However, upon PEG inclusion, there seemed to be increased optimal binding for the 
SM2(+PEG) derivative while the acetylated SM3(+PEG) maintained an optimal N:P 
binding ratio of 2.5:1. The corresponding optimal N:P weight ratios as observed in Table 
3.2, showed comparable ratios for the unPEGylated derivatives. Higher optimal N:P 
weight ratios were observed for the PEGylated derivatives with the highest weight ratio 
obtained for the SM2(+PEG) derivative. 
 
It is interesting to note that the PEGylated derivatives viz. SM1(+PEG), SM2(+PEG) and 
SM3(+PEG) did not exhibit distinct obvious end-points. There was seemingly weaker 
binding avidity for DNA compared to their unPEGylated derivatives. Migration patterns 
of DNA with these liposomes exhibited what appeared to be streaking of the pDNA down 
the gel. This streaked or smeared DNA did not comprise either the circular or supercoiled 
conformations and rendered it difficult to determine the exact end-point ratios. The point 
at which distinct bands of DNA were no longer visible as distinct bands on the gel was 
accepted as the end-point ratio. Thus the PEGylated derivative as seen in (b) and (d) were 
assumed to bind the pDNA at a ratio of 3:1 for SM1(+PEG) and SM2(+PEG) and 2.5:1 
for SM3(+PEG), respectively - albeit in an unconvincing manner. This general 
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characteristic of reduced DNA-binding abilities observed in PEGylated derivatives has 
been reported by other authors (Zhang et al., 2010; Singh et al., 2011) 
 
Another possible explanation relates to the partial shielding of the cationic headgroups by 
the PEG polymer chains, which impedes their interaction with DNA (Templeton, 2002). 
It has been established that grafting densities of PEG will generally influence 
conformational disposition and configuration assumed on the liposomal surface. Grafted 
PEG 2000 will most likely result in the brush regime where the polymer projects by 50Ǻ 
from liposomal surface. This can result in strong intermembrane repulsive forces leading 
to reduced DNA-liposome interactions. These effects may be compounded by the water 
shell resulting from the PEG polymer surrounding the liposomal surface (Immordino et 
al., 2006; Daniels et al., 2011; Gorle et al., 2014). However, Daniels et al., (2011) 
reported that liposomes comprising DSPE-PEG2000 at 5 mol% had resulted in complete 
retardation of plasmid DNA.  
 
Acetylation and PEGylation in SM3 and SM3(+PEG) derivatives surprisingly resulted in 
better associations with DNA. This is despite the assumption that the negatively charged 
acetyl groups would not allow for tight DNA-binding. However, it must be noted that the 
acetylated SM3 liposome had in fact retained positive charge measured at zeta potential 
of +14.27 mV far better than its SM2 counterpart at +2.36 mV. This would lead to better 
interactions with the negatively charged DNA. This is in contrast with reports showing 
acetylated and PEGylated dendrimers which displayed less condensed DNA when 
complexed with acetylated dendrimers when compared to the unmodified dendrimers 
(Fant et al., 2010).  
 
The lipoplexes assembled at the optimal, sub- and super-optimal DNA-binding ratios 
were explored further with respect to their nuclease-resistance, cytotoxicity and 
transfection potential. 
 
3.2.2 Ethidium bromide intercalation assay 
 
The ethidium bromide intercalation assay is routinely carried out in order to monitor and 
evaluate the ability of liposomes to condense and compact the DNA using the monovalent 
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DNA-intercalating agent, ethidium bromide. The DNA-intercalated ethidium bromide 
dramatically enhances fluorescence, but it is quenched when it is displaced by higher 
affinity compounds that bind to DNA e.g. when adding liposomes to form complexes 
with the DNA (Tros de Ilarduya et al., 2010).  
 
Cationic liposome preparations are known to displace DNA-associated ethidium. By 
stepwise addition of cationic liposomes to the ethidium bromide-labeled DNA, 
condensation by liposomes results in stepwise displacement of the ethidium bromide and 
leads to reduced fluorescence (Pires et al., 1999; Singh and Ariatti, 2006).  
 
The control liposome SM1 and its PEGylated derivative, SM1(+PEG) (Figure 3.5) 
showed that upon stepwise addition of the respective liposomal formulation, a point of 
inflection was observed, which as  at approximately 70% relative fluorescence. This point 
corresponded with the complete association of DNA with liposomes which also 
corresponded to the optimal N:P weight ratio of just above 4 as determined by gel 
retardation analysis. This is in confirmation of the results obtained in the gel retardation 
assay. The PEGylated SM1 derivative was observed to exhibit a reduced drop in 
fluorescence, which relates to looser associations with DNA compared to the 
unPEGylated derivative. This was in agreement with results obtained by Gorle et al. 
(2014) where ethidium displacement was greatest with untargeted unPEGylated 
liposomes than in the PEGylated-untargeted lipoplexes. 
 
This trend is also seen in the targeted unPEGylated derivatives viz. SM2 and SM3 which 
showed far better condensation of DNA that their PEGylated derivatives (Figure 3.6).  
The targeted-PEGylated complexes also displayed a somewhat compromised quality of 
DNA condensation. This can be explained by the PEG shielding effect where the cationic 
charges of the liposomes lead to reduced interactions with the pDNA. PEGylation has 
been said to significantly reduce pDNA binding affinity of DC-Chol/DOPE liposomes 
(Chen et al., 2013). In a study by Fant et al. (2010), availability for ethidium intercalation 
was observed to be significantly higher in the DNA-dendrimer complexes comprising 
acetylation and PEGylation modifications than in unmodified ones (Fant et al., 2010). 
Additionally, low grafting density is essential so that the „mushroom‟ regime assumed 
results in limited effect on the binding affinity of DNA to liposomes. At higher grafting 
density, the brush conformation can limit DNA interaction with the cationic headgroups 
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projected on the liposomal surface.  In that instance, binding of DNA to the liposomal 
cationic headgroup can be found to be much looser and tenuous (Daniels et al., 2011; 




Figure 3.5 Ethidium bromide interaction assays with stepwise addition of untargeted 
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Figure 3.6 Ethidium bromide interaction assays with stepwise addition of targeted 
liposomes SM2, SM3, and their PEGylated SM2(+PEG) and SM3(+PEG) derivatives. 
Arrow indicates point of inflection. 
 
A sharper point of deflection was observed for the acetylated SM3 liposome which was 
observed at 40% displacement while a much steadier decline in fluorescence was 
observed for the SM2 liposome. For both these derivatives, the plateau points were 
reached at the correspondingly higher weight ratios. Other authors have reported a trend 
where targeting moieties such as β-D-galactopyranosyl resulted in higher N:P end-point 
ratios than untargeted derivatives (Dorasamy et al., 2012; Gorle et al., 2014). Once a 
plateau is reached, any further addition of liposome was observed to result in more 
modest reductions in fluorescence. This suggests that there was no further significant 
pDNA condensation beyond this point. 
 
3.3 Serum nuclease digestion assay 
 
Efficient gene delivery requires that the DNA cargo be protected from adverse effects of 
serum components.  These include, but are not limited to, structural alterations of lipoplex 
structure which may lead to digestion by serum nucleases (Resina et al., 2013). In this 
assay, the binding interaction of the DNA and liposome are investigated for their ability 

































Lanes 1 in Figures 3.7 and 3.8 show the untreated DNA displaying the three DNA 
conformations, viz. linear, closed circular and superhelical.  Lanes 2 represent the 
unbound naked DNA which is exposed to serum and is visibly digested by the nucleases.  
Lanes 3, 4 and 5 contain increasing ratios of liposome:DNA which conferred different 
degrees of protection. The untargeted control SM1 demonstrated good protection of the 
DNA in increasing ratios; however, there is evidence of nicking of the superhelical DNA 
(Figure 3.7). This is observed with the disappearance of this band, while the closed 
circular DNA is retained. PEGylated derivative SM1(+PEG) exhibited similar protection 
patterns and nicking of the superhelical DNA is evident in all ratios. The greatest 
susceptibility was observed in the PEGylated SM1(+PEG) liposome as the N:P ratio 
decreased to 2.5:1. This could be related to the unbound DNA molecules which are 




    
   
Figure 3.7 Serum nuclease digestion assays for liposomes: A) lanes 3-5: SM1 at N:P 
ratios of 2:1,2.5:1, 3:1 and 3.5:1, respectively and B) lanes 3-5: SM1(+PEG) at N:P ratios 
of 2.5:1,3:1 and 3.5:1, respectively. 
 
 






     
  
Figure 3.8 Serum nuclease digestion assays for liposome‟s: A) lanes 3-5: SM2 at N:P 
ratios of 2:1,2.5:1, and 3:1, respectively; lanes 6-8:  SM2(+PEG) at N:P ratios of 3:1, 
3.5:1 and 4:1, respectively; and B) lanes 3-5: SM3 at N:P ratios of 2:1, 2.5:1 and 3:1, 
respectively; lanes 6-8: SM3 (+PEG) at N:P ratios of 2:1,2.5:1 and 3:1, respectively. 
 
The targeted SM2 liposome was also observed to provide partial protection of the DNA 
from nuclease degradation at all ratios as seen in Figure 3.8. However, the integrity of the 
protected pDNA had been preserved as seen by presence of both linear and closed 
circular conformations. A similar protection pattern was observed for PEGylated 
derivative SM2(+PEG). The acetylated SM3 liposome and its PEGylated derivative also 
resulted in compromised protection for the pDNA cargo. What was different with these 
derivatives however, was the evident nicking of the superhelical pDNA as its band is not 
seen on the gel.  The least protection was afforded by the SM3 complex at the lowest N:P 
ratio of 2:1 as it resulted in complete degradation of the pDNA cargo. However, at 
optimal ratios, both SM3 and SM3(+PEG) resulted in increased band intensity of the 
closed circular form of DNA. This evidently suggested that nicking resulted in increased 
amounts of closed circular DNA being protected. 
 
3.4 Assembly of lipoplexes 
 
Significant changes take place with regards to the physico-chemical features of cationic 
liposomes upon complexation with negatively charged nucleic acids (Pires et al., 1999; 
Madeira et al., 2011; Paecharoenchai et al., 2012).  
 





3.4.1 Cryo-TEM of lipoplexes 
 
Morphological characteristics of lipoplexes can be examined using cryo-TEM. Lipoplex 
structure has been linked to transfection efficiency, whereby size and shape of complexes 
can influence the internalisation pathway to be taken (Van Groll et al., 2006; Madeira et 
al., 2011). While cryo-TEM is a more reliable method of visualisation, it is limited due to 
low contrast which can result in some details not being observed. Additionally, the 
sample observed is not representative of the entire lipoplex population. 
 
Lipoplexes prepared at liposome:DNA ratio corresponding to the minimum liposome 
suspension required to bind fully 0.5 µg DNA were investigated. Micrographs showed 
varied arrangements seen as globular aggregates and predominantly cluster organisations 
of unilamellar vesicles (Figure 3.9). The distinct necklace-like structures observed in 
SM2(+PEG) (Figure 3.9 D) have been reported to be characteristic of linearised DNA 
complexes, while compact aggregates are commonly associated with circular DNA 
complexes (Van Groll et al., 2006). An analysis of lipoplexes containing DOPE showed 
that DNA molecules are often sandwiched between the lamellae in exhibiting clustered 
multilamellar structures. Cationic lipoplexes containing cholesterol-based cytofectins 
have previously been reported to have exhibited compact aggregates (Ropert, 1999; Singh 





Figure 3.9 Cryo-TEM images of lipoplexes showing spherical vesicles arranged in linear  
as well as clustered aggregates. A) SM1, B) SM1(+PEG), C) SM2, D) SM2(+PEG), E) 






The complex mean diameters of the untargeted control lipoplexes were found to range 
from 65 nm to 120 nm. The largest particle sizes were measured for targeted lipoplexes of 
SM2 and SM3 at ~ 250 nm. The PEGylated derivatives viz. SM1(+PEG) and 
SM2(+PEG) yielded lipoplexes which were marginally smaller, and consistent with what 
is expected for PEGylated formulations. Lipoplexes formed as a result of nucleic acids 
interacting with unilamellar vesicles of cationic lipids such as DOTAP combined with 
DOPE and cholesterol have been reported to result in multilamellar organisations, 
whereby the DNA is intercalated between the cationic lipid bilayers (Montier et al., 
2008).  
 
3.4.2 Size and zeta potential measurements of lipoplexes 
 
Size measurements of the complexes by DLS were given as a mean diameter (z-average). 
Generally, an increase in vesicle size is a result of reduced electrostatic interactions 
following association with pDNA.  This in turn results in the tendency of lipoplexes to 
aggregate, thereby forming larger complexes (Mogghadam et al., 2011). Complexation 
with DNA resulted in an increase in vesicle size for all liposomal formulations with a 
relatively homogenous size distribution (Table 3.3). 
 
Table 3.3 Size distribution and zeta potential measurements for the lipoplexes using DLS 
 Z-average (nm) PDI value ζ-potential (mV) 
SM1 1163.00±15.72 0.237 ˗25.93 
SM1(+PEG) 99.76±1.56 0.241 ˗5.13 
SM2 935.30±16.89 0.186 ˗28.00 
SM2(+PEG) 102.77±0.75 0.264 ˗5.24 
SM3 433.67±8.41 0.259 ˗15.37 





The untargeted and unPEGylated SM1 lipoplex displayed the largest vesicle size at over 
1000 nm with a relatively narrow distribution of 0.237. Size diameters greater than 1000 
nm of unPEGylated and untargeted lipoplexes of comparable composition were 
previously reported (Gorle et al., 2014). These could also be explained in terms of 
stability properties, where the unPEGylated untargeted may aggregate and vesicle fusion 
processes could then result in larger complexes. The rigidity conferred by cholesterol 
ensures regular positioning of the positively charged cytofectin head groups on the lipidic 
surface. Thus upon interactions with DNA, there can be a formation of colloidally stable 
and negatively charged complexes, with excess uncondensed DNA surrounding the 
lipoplexes (Turek et al., 2000; Ferrari et al., 2002). 
 
Targeted liposomes gave rise to complexes with smaller size diameters compared to the 
untargeted SM1. Dorasamy et al. (2012) suggested that galactosylation may result in 
inhibition of vesicle fusion, thus affording smaller complex sizes compared to the non-
targeted complex. SM2 measured an average of ~935 nm while SM3 with acetylated 
galactoside Sc9 displayed the lowest size diameter of ~434 nm. Although SM3 liposome 
had presented a larger diameter compared to SM1 and SM2, the resulting complexation 
with DNA led to the most compact lipoplex size. What is noteworthy, and may explain 
these results is that the acetylated SM3 liposomes displayed the most positive surface 
charge. This would have led perhaps to better liposome:DNA interaction. It is quite 
possible that the acetyl groups adjacent to the cationic head also contributed to the head 
group interactions with the DNA phosphodiester negative charges.  
 
Significant size compaction for all three PEGylated derivatives was noted when 
associated with DNA. The greatest and most significant reduction was observed for the 
untargeted control SM1(+PEG) at size diameter of 99.76 nm. Both SM2(+PEG) and 
SM(+PEG) exhibited reduced size diameters of 102.77 nm and 126.87 nm, respectively.  
This can be related to PEG properties where steric hindrance is conferred and reduced 
aggregations discouraged vesicular fusion to form larger vesicles (Pannier et al., 2008). 
Similar results were obtained by Chen et al. (2013) where incorporation of 6.25 mol% 
PEG led to reduced size and surface charge density of lipoplexes. PEG concentrations of 
5 mol% have been previously reported to result in retention of positive cationic charge 
(Campbell et al, 2002). This was however, not the case as PEG resulted in some masking 
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of the positive charges of the head group and DNA condensation led to net negative 
charge in these lipoplexes, attributable to uncondensed DNA. 
 
PDI values for untargeted SM1 and its PEGylated derivative SM1(+PEG) were found to 
be within a range of 0.237 and 0.241 indicating homodispersion or homogeneity in size 
distributions.  This was consistent with the targeted SM2, SM3 and their PEGylated 
derivatives, SM2(+PEG) and SM3(+PEG) which also displayed fairly narrow size 
distribution with PDI values ranging from 0.186 to 0.268.  
 
Lipoplex structure, and its biological activity is influenced by surface charge on the 
liposomes prior to complexation (Ferrari et al., 2002). In cationic liposomes, it is the 
charge density of the cationic moiety at the surface of liposomes that influences their ζ-
potential. It is also an important parameter which contributes to transfection efficiency 
(Takeuchi et al., 1996; Nie et al., 2011). Overall, reductions in ζ-potential values were 
observed for all lipoplex formulations. In a study by Pires et al. (1999), complexation of 
DNA with DOTAP-containing liposomes led to decreased ζ-potential values. Reduction 
in surface charge is suggested to be beneficial for DNA dissociation from the lipoplex 
following uptake by the cells (Mogghadam et al., 2011). UnPEGylated derivatives viz. 
SM1, SM2 and SM3 resulted in relatively stable complexes. Before DNA complexation, 
the overall charge was +13.53, +2.36 and +14.27 mVs (Table 3.2), respectively and upon 
binding with DNA, these values were reduced to ˗25.93, ˗28.00 and ˗15.37 mVs (Table 
3.3), respectively. An excess of positive or negative charge of >+30 and <˗30 mV is 
believed to confer sufficient electrostatic repulsive forces to prevent aggregation (Salopek 
et al., 1992; Nie et al., 2011). SM1 and SM2 can thus assumed to be the most stable 
complexes when compared to SM3 as they measured ζ-potentials of ˗25.93 and ˗28.00 
mVs, respectively. 
 
Figure 3.10 presents a distribution pattern of the lipoplexes where the PEGylated 
derivatives are observed in the near-neutral zone with size ranges below 200 nm.  
However, the unPEGylated derivatives suggest that an increase in average size diameter 
corresponds with a decrease in surface charge. It seems that a correlation could be drawn 
with the liposomes we have, where an increase in diameter resulted in decrease in zeta 





Figure 3.10 Size distribution of lipoplexes in relation to zeta potential 
 
Marginal reduction in surface charge was observed for the stable complexes with 
PEGylated derivatives viz. SM1(+PEG), SM2(+PEG) and SM3(+PEG). Addition of 
DSPE-PEG2000 in complexes has been reported to promote stabilisation in complexes (Hu 
et al., 2010). The final surface charge remained in the ˗5 mV range, which places it within 
the neutral zone. SM2(+PEG) was found to exhibit the most negative surface charge at 
˗5.24 mV. Reduction of neutral ζ-potential value to a negative charge could be attributed 
to the phosphate groups in DSPE. The negative values obtained with the use of DSPE-
PEG2000 could be attributed to the presence of negative PEG dipoles that can form a 
mushroom/brush intermediate PEG conformation (Morille et al., 2008; Kibria et al., 
2011). While extensive aggregation and fusion would be favoured in the case of neutral 
complexes, steric hindrance conferred by PEG results in their stability. There is general 
assumption that positively charged liposomes should maintain positive charge even after 
interaction with the negatively charged DNA in order to facilitate interaction with target 
cells. However, numerous literature reports have stated that in vivo application of 
positively charged lipoplexes does not always guarantee higher transfection. In fact, these 
are prone to rapid clearance from circulation due to binding with anionic plasma 
components (Wasungu and Hoekstra, 2006). Additionally, some authors have reported on 
negatively charged lipoplexes which have not been impeded in their transfection potential 
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3.5 In vitro evaluation of lipoplexes on HEK293 and HepG2 cell lines 
3.5.1 Cytotoxicity assay 
 
Early studies in non-viral gene delivery related transfection efficacy in terms of carrier  
binding affinity to nucleic acids or drugs, encapsulation efficiency, biodistribution 
following administration, and uptake by cells for expression.  Cationic lipids particularly, 
being membrane active may interfere with membrane function and cell integrity which 
can ultimately lead to toxicity.  Thus safety remains a critical factor in their application in 
vivo (Romørren et al., 2004; Paecharoenchai et al., 2012; Wang et al., 2012).  
 
Cytotoxicities of formulated lipoplexes were assessed at liposome:DNA sub-optimal, 
optimal and super-optimal ratios using the MTT assay. The biochemical reaction is based 
on metabolically active cells, which are able to reduce 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide solution to form purple, insoluble MTT formazan crystals. 
Viable cell density is thus related to functional mitochondrial enzymes responsible for 
MTT reduction (Rodrigues et al., 2012). Figures 3.11 and 3.12 represent cytotoxicities of 
lipoplexes in HEK293 and HepG2 cell lines, respectively.  
 
All liposomal formulations including the PEGylated derivatives presented an above 
average cell viability greater than 60% at optimal binding ratios in the HEK293 cell line. 
At these optimal ratios, the highest cell viabilities >80% were observed for the control 
liposome SM1, the targeted SM3 and their PEGylated derivatives, viz. SM1(+PEG) and 
SM3(+PEG). Neutral lipids have been associated with lower cytotoxicities due to reduced 
interactions with serum (Simões et al., 2005). The degree of PEGylation has been 
observed to reduce cytotoxicity in DC-Chol/DOPE complexes where 5 mol% DSPE-PGE 
showed the least cytotoxic effect (Chen et al., 2013). However, SM2 and its PEGylated 
derivative presented with lowest cell survival at 65% and 62%, respectively. The 
observed toxicities could be linked to compromised membrane integrity resulting from 
increased interactions with serum components (Singh and Ariatti, 2006). The acetylated 
SM3 and its PEGylated derivative resulted in the highest cell viabilities.  This has been 
reported extensively in other systems where these modifications, viz. acetylated and 
PEGylation were found to result in reduced cytoxicities of dendrimers (Fant et al., 2010; 




Figure 3.11 Cell viability studies of lipoplexes for the HEK293 cell line in varying 
amounts of liposome corresponding to the optimal, sub- and super-optimal DNA-binding 
ratios. Each column represents the mean ± SD (n = 3). *P < 0.05 vs control 
 
 
Figure 3.12 Cell viability studies of lipoplexes for the HepG2 cell line in varying 
amounts of liposome corresponding to the optimal, sub- and super-optimal DNA-binding 
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Lower liposomal concentrations resulted in reduced cell growth inhibition for most of the 
liposomal formulations. Cell viabilities >100% were also observed in HEK293 cells and 
may arise through metabolised components of the liposomes promoting cell growth. 
Untargeted lipoplexes SM1 and its PEGylated derivative SM1(+PEG) resulted in above 
average cell viability of >65% in HepG2 cell line as shown in Figure 3.12. The targeted 
lipoplexes resulted in relatively greater cytotoxicities up to 38% when compared to the 
untreated control. The SM2(+PEG) lipoplexes were well-tolerated by the HepG2 cells 
with cell viability above 80% while the acetylated SM3 resulted in cell viabilities of 
~70%. Hepatotoxic effects were reported for siRNA lipoplexes formulated with Sc9 
ligands. These led to increased levels of circulating interleukin-6 and tumour necrosis 
factor following the fourth injection of these complexes in an animal study (Hean et al., 
2010). And thus, this remains an important factor to consider when it comes to in vivo 
application. 
 
Earlier reports by Singh and Ariatti (2006) had demonstrated that cationic lipoplexes 
result in growth inhibitions of up to 31% for HepG2 cell lines. Upon investigations by 
Dorasamy et al., (2011), galactosylated Chol-T siRNA lipoplexes were well-tolerated by 
the HepG2 cells at viabilities > 80%. At ratios below liposome:DNA optimal binding, 
there was increase in cell viabilities for all liposomal formulations.  An increase in 
liposome:DNA ratios did not result in significantly lower cell viabilities thus suggesting 
that the liposomes do not present adversely cytotoxic effects for the HepG2 cells.  
Lipoplexes that comprise cholesterol and DOPE have been reported to display good cell 
compatibility (Yang et al., 2013). Growth inhibitions of up to 18% were reported for 
CholβGal and CholαGal lipoplexes comprising co-helper DOPE in Hela and HepG2 cell 
lines (Singh et al., 2007).   
 
3.5.2 Transfection assays 
 
The luciferase assay employs the pCMV-luc reporter gene vector for expression of the 
luciferase gene. Cells which had been successfully transfected with the luc gene were 
lysed, and excess substrate (D-luciferin) was added to the lysate generating luminescence 
(De Wet et al., 1987). The intensity of the light emitted was quantified and taken as a 
measure of gene expression level.  This is directly proportional to the quantity of the 
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enzyme present in the cell lysate. Results were normalised by determining the soluble 
protein concentration in the lysate and results were expressed as relative light units 
(RLU)/µg protein. 
 
An overall assessment of gene expression levels was conducted in the ASGP receptor-
negative HEK293 cell line by lipoplexes viz. SM1, SM2 and SM3 and their PEGylated 
derivatives at N:P ratios below, above and at optimal points. The controls are classified 
as: (˗)control, where there was no DNA added, and (+)control, where naked uncomplexed 
DNA was added to the cells (Figure 3.13).  
 
The untargeted SM1 derivative was observed to result in comparably high transfection to 
that achieved by the other smaller-sized liposome derivatives. Size has been determined 
to influence choice of internalisation pathway and ultimately, the fate of the lipoplexes 
(Rejman et al., 2004; Khalil et al., 2006). SM1 presented with the highest complex size 
diameter of over 1000 nm, followed by the targeted SM2 at 935 nm. Cellular uptake for 
these complexes could have been resulted from phagocytosis, clathrin-mediated 
endocytosis, caveolae-mediated endocytosis or macropinocytosis. It has been proposed 
that cationic complexes without the targeting moiety are internalised as a result of various 
endocytotic routes. PEI-DNA complexes were proposed to be internalised following 
binding of the complex with the transmembrane heparin sulphate proteoglycans. This 
leads into clustering into cholesterol-rich lipid rafts which pulls the complex into the cell 
via phagocytosis. Cationic lipoplexes were reported to interact with proteoglycans where 
lack of proteoglycans resulted in complexes being unable to transfect Raji cells in vitro. 
The clathrin-mediated endocytosis could only have been achieved following 
fragmentation of the complexes into smaller units (Rejman et al., 2004; Khalil et al., 
2006; Ma et al., 2007; Minzter and Simanek, 2009).  
 
There is also preferential uptake via caveolae-mediated transfection for particles with  
sizes ranging >200 nm to 1 000 nm in diameter. This would explain the comparatively 
high transfection efficiencies noted for all unPEGylated liposomes viz. SM1, SM2 and 







Figure 3.13 Transfection capabilities of A) SM1 and SM1(+PEG), B) SM2 and 
SM2(+PEG) and C) SM3 and SM3(+PEG) lipoplexes in HEK293 cell line at varying 
amounts of liposome corresponding to the optimal, sub and super-optimal DNA-binding 
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While it may not be an ideal situation to have particles as large as 935 nm or 434 nm in 
the in vivo setting, larger sizes have been reported to result in enhanced sedimentation 
thus allowing for maximum contact with the cells in vitro. Optimal sizes for high 
transfection in vitro have been suggested to lie between 200 nm – 400 nm. 
Macropinocytosis has been reported to lead to uptake of larger sized cationic lipoplexes 
for efficient transfection Again, while these pathways are not necessarily mutually 
exclusive, it cannot be concluded that all of them result in productive transfection 
(Rejman et al., 2004; Simões et al., 2005; Ma et al., 2007; De Garibay et al., 2013).  
 
Another important aspect relates to serum effects. Interactions with serum components by 
larger lipoplexes have been reported to result in lower transfection due to decreased 
delivery and dissociation of the complexes. However, in a contrasting report, large 
cationic complexes of over 700 nm have been observed to result in enhanced transfection 
due to delayed dissociation of the lipid from DNA (Fumoto et al., 2005; Ma et al., 2007). 
For particles with size diameters less than 250 nm, the clathrin-mediated pathway would 
be the most likely internalisation pathway for complexes in this size range. This is the 
suggested internalisation pathway for the PEGylated SM1(+PEG), SM2(+PEG) and 
SM3(+PEG) derivatives as they presented size diameters less than 126 nm at optimal 
ratios (Simões et al., 2005; Khalil et al., 2006; Ma et al., 2007; Minzter and Simanek, 
2009).  
 
Surface charge is an equally important determining factor in how the complexes interact 
with the target cell membrane (Zuhorn et al., 2007). The unPEGylated derivatives of 
SM1, SM2 and SM3 presented with net negative charges of -22.93, -28.00 and -15.37 
mVs, respectively. It would be expected that this would render the complexes incapable 
of interacting with the cell membrane. However, comparably high transfection 
efficiencies were noted for all these derivatives at optimal binding ratios. Negatively 
charged lipoplexes are often associated with lower stability due to aggregation. According 
to one report, a zeta potential with a range of ~-5 mV to -15 mV is said to be ideal for 
nanoparticles designed for biological systems (Leary, 2011). The PEGylated derivatives 
presented stable complexes with near-neutral charges. While it has been suggested that a 
fall of net positive charge to neutrality can result in inhibited transfection, this was not the 
case for these liposomes. This relates to the steric hindrance afforded by PEGylation 
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which does not allow aggregation (Simões et al., 2005; Ma et al., 2007; Xiang and Zhang, 
2013). 
 
Overall results showed higher transfection levels by liposomes in HepG2 cells when 
compared to HEK293 cells (Figure 3.14). Cell type-dependent differences in transfection 
efficiencies relate to cell cycle and cell division frequency and the cells‟ endocytic 
capacity. Transfection efficiencies of F108-coated DNA lipid nanocapsules (LNC) in 
HeLa cells were reported to be slightly superior to those in H1299. It is also quite 
possible that the different optimal cell densities required to carry out the transfection 
assays is cell type-dependent.  Lipofectamine 2000 optimal cell densities are reported to 
be higher in HEK293 cells for the β-galactosidase assay and lower in luciferase gene 
expression assay for the HeLa cells (Zuhorn et al., 2007; Wang et al., 2012). 
 
The untargeted SM1 derivative showed the overall lowest transgene activity, with the 
exception of the super-optimal N:P ratio. This could be explained in terms of the complex 
large size diameter of over 1000 nm. In a study by Ross and Hui (1999), it was 
determined that an increase in size of larger lipoplexes results in greater cellular 
association and uptake when compared to smaller complexes. This is attributed to the 
larger surface area presented by the larger complexes making uptake more favourable. 
Once taken up by the cells, it is believed that larger lipoplexes result in large intracellular 
vesicles which can be disrupted more easily for release of DNA into cytoplasm (Ma et al., 
2007; Mintzer and Simanek, 2009; Malaekeh-Nikouei et al., 2009). The lower 
transfection efficiency for the sub-optimal and optimal ratios could be attributed to the 
serum effects on large lipoplexes. Introduction of serum to large DC-Chol/DOPE 
lipoplexes results in adsorption of large amounts of pDNA onto their cationic surfaces.  
This has been found to confer the excess negative charge onto the lipoplex surface. This 
can lead to reduced interactions of the cationic lipids with the endosomal membrane and 
ultimately interfere with the membrane hexagonal phase transition for endosomal escape. 
Additionally, it can result in conversion of the supercoiled structure of the pDNA to the 
open-circular conformation which is transcribed less efficiently. Thus there is low 
transfection efficiency exhibited by these lipoplexes (Malaekeh-Nikouei et al., 2009; 






Figure 3.14 Transfection capabilities of A) SM1 and SM1(+PEG), B) SM2 and 
SM2(+PEG) and B) SM3 and SM3(+PEG) lipoplexes in HepG2 cell line at varying 
amounts of liposome corresponding to the optimal, sub and super-optimal DNA-binding 
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The PEGylated derivative SM1(+PEG) lipoplex however, presented a mean size range of 
99 nm at optimal ratio, and a near neutral zeta potential (˗5 mV) with  higher transfections 
being noted. Small liposomes with diameters below 100 nm are reported to have 
relatively easy access to the transendothelially located hepatocytes, even without using 
any targeting ligand. This is related to size restrictions of 175 nm for traversing through 
the fenestrae into the Disse space (Hattori et al., 2000; Bae and Park, 2011; Patil and 
Jadhav, 2014). However, the observed transfection results for the untargeted SM1(+PEG) 
were somewhat unexpected as they were comparable and even higher than those of 
targeted SM2, SM3 and their PEGylated derivatives viz. SM2(+PEG) and SM3(+PEG). 
However, Morille et al. (2008) also reported that galactosylated DNA LNCs were as 
efficient in transfecting primary hepatocytes as the untargeted DOTAP/DOPE lipoplexes. 
At this size range of ~120 nm, the main mode of internalisation could be as a result of 
adsorptive clathrin-mediated endocytosis. The near-neutral zeta potential (within the ~ ˗5 
mV range) also advantageously played a significant role in terms of interactions with the 
cell membrane. Reduction in surface charge of cationic lipoplexes is assumed to be 
beneficial for DNA dissociation following cellular uptake for trafficking to the nucleus 
(Zuhorn et al., 2007; Moghaddam et al., 2011).  
 
It has been suggested that size effects are probably more pronounced in targeted 
complexes when compared to the non-targeting counterparts (Minzter and Simanek, 
2009). The targeted SM2 derivative presented a complex with negative zeta potential 
which was ˗25 mV, and a size diameter of ~935 nm at optimal N:P ratio. While it is 
believed that size ranges between 650 nm to 1500 nm are likely to be internalised via the 
caveolae-mediated pathway, and thereby avoid lysosomal degradation – this does not 
guarantee high transfection levels (Zuhorn et al., 2007; Brgles et al., 2012). Again, these 
parameters can be altered under serum-present conditions, resulting in lower transfection 
efficiency. For instance, larger complexes will tend to display a weakened ability to 
protect DNA following interactions with serum.  Thus while they are able to escape from 
the endosomes efficiently, they often result in poor transfections. This was observed to be 
true particularly for the sub-optimal ratio in SM2 lipoplex. At this ratio, the liposomes did 
not afford optimal serum nuclease protection for the DNA cargo as there was some 
degradation of the DNA cargo (Yang et al., 2013). Its PEGylated derivative viz. 
SM2(+PEG) was however, observed to display relatively better transfection efficiency. 
Inclusion of PEG led to improved transfection efficiency by enhancing stability and as a 
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result of desirable size reduction. Literature reports have indicated that galactosylated 
lipoplexes with a mean size of 141 nm result in higher transfection in parenchymal cells 
in vivo. While size could be the main contributing factor, stability and efficacy in serum is 
said to be critical for successful delivery (Singh et al., 2007). 
 
The highest gene expression levels were noted for the unPEGylated SM3 at optimal ratio. 
The acetylated SM3 lipoplexes led to sustained transfection owing to their favourable zeta 
potential (15 mV), and size diameter (434 nm). Size could be an important contributing 
factor where moderately sized vesicles of 400 nm were reported to result in higher 
transfection efficiency (Malaekah-Nikouei et al., 2009). Another interesting aspect relates 
to the serum degradation assay results, which showed nicking of the supercoiled pDNA 
thus resulting in the prevalence of open circular pDNA. Van Groll (2006) reported that 
while linearised DNA presents a more stable DNA conformation, they exhibit lower 
transfection efficiency compared to circular complex.  In fact, it was observed that when 
complex size diameter ranged from 100 to 500 nm using circular pDNA, there was 
accentuated transfection efficiency. 
 
While targeting is important, it remains critical to contextualise it in terms of other 
contributing factors that impact on transfection efficiency.  This was particularly evident 
in the case of the SM3(+PEG) lipoplexes with acetylation and PEGylation modifications. 
The SM3(+PEG) lipoplex exhibited the overall lowest transfection efficiency when 
compared to the other targeted lipoplexes. Transfection efficiency of acetylated and 
PEGylated dendrimers was also observed to be lower than that of the corresponding 
unmodified dendrimers (Fant et al., 2010). Slightly better transfection efficiency levels 
were observed for the sub-optimal ratio; however, it was almost abolished at optimal and 
super-optimal N:P binding ratio. This was despite the enhanced stability properties where 
a 120 nm size diameter and near neutral surface charge were reported.  
 
This can, perhaps, be explained in respect of the PEG dilemma. PEGylation has been 
reported to lead to reduced association with the target cell membrane, but in context of 
targeted delivery, it could result in masking of the galactose moiety. While it has been 
established that DSPE-PEG2000 confers a mushroom/brush intermediate or mushroom 
spatial conformation for accessibility of the galactose moeities, it could still present an 
impediment. In a folded conformation, the galactose moiety might be hidden (Morille et 
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al., 2010). Morille et al (2010) also reported similar results in the sterically stabilised 
DNA LNCs with DSPE-mPEG2000 that displayed reduced transfection efficiencies in 
comparison to non-coated DNA LNCs in H1299 and HeLa cell lines. This remains the 
primary drawback of PEG and is attributed to the obstructed association with target cells.  
Additionally, PEG can be an impediment in endosomal escape due to the lower surface 
charge on lipoplexes, although this was not observed in the case for the SM2(+PEG) 
lipoplexes (Morille et al., 2010). The 120 nm size often results in clathrin-mediated 
endocytosis, but is subject to rapid processing and clearing. This, coupled with an 
impeded dissociation of lipoplexes from the endosomes would have resulted in poor 
transfection efficiency. Size-dependent variations in transfection results have been cited 
in various literature reports (Mintzer and Simanek, 2009). And thus, the results of the 
unPEGylated SM3 derivatives can also explained by the possibility  that the ligand could 
have been more readily accessible, thus resulting in better receptor recognition and 
increased transfection efficiency than its PEGylated counterpart. 
 
To verify the ASGP receptor-mediated internalisation, a competitive inhibition study was 
carried out for targeted lipoplexes viz. SM2, SM2(+PEG), SM3 and SM3(+PEG) as seen 
in Figure 3.15. Asialofetuin is a natural ligand which shows strong affinity for the ASGP 
receptor. It has three asparagine-linked triantennary complex carbohydrates with terminal 
N-acetyllactosamine (LacNAc) residues.  
 
Upon addition of the competitive inhibitor, asialofetuin, a marked decrease of up to 2 
order of magnitude in transfection activity was noted for the SM2 and SM2(+PEG) 
lipoplexes. This undoubtedly showed that the ASGP receptor had been saturated by 
asialofetuin thereby preventing ASGP receptor-mediated internalisation and expression of 
the pCMV-luc gene. This was also observed in the SM3 and SM3(+PEG) derivatives 
where the most significant reduction was observed for the optimal ratio in SM3 and the 
sub-optimal ratio of SM3(+PEG). This was clear evidence of the ASGP receptor-
mediated endocytosis; however, the effects were less pronounced for the low transfecting 









Figure 3.15 Transfection capabilities of A) SM2 and SM2(+PEG); and B) SM3 and 
SM3(+PEG) lipoplexes in varying amounts of liposome corresponding to the optimal, 
sub- and super-optimal DNA-binding ratios for the  HepG2 cell line in presence of 
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Overall, targeting of the ASGP receptor was found to present the main mode of 
internalisation of lipoplexes and eventual gene expression in the SM2, SM3 and their 
PEGylated derivatives.  However, it must be stated that internalisation modes are not 
mutually exclusive and can thus occur simultaneously (Zuhorn et al., 2007). The 
unPEGylated SM3 comprising of the acetylated Sc9 galactoside presented with superior 
transfection effiencies in both the HEK293 and HepG2 cell lines.  
 
3.6 In silico evaluation of ligand-receptor interactions 
 
Docking analyses serve to predict the in vivo setting in respect of bound conformations 
and their binding affinity (D‟Souza et al., 2013). Figures 3.16 and 3.17 illustrate the 
docked pose by the Sc6 and Sc9 galactoside ligands to the ASGP receptor using Ligplot. 
The conformation shown in Figure 3.16 demonstrates the best docked pose of the Sc6 
galactoside in the receptor binding site. It takes into account the coordinate bonds, 
hydrophobic bonds, and hydrogen bonds, all critical in ligand-receptor interactions. In 
particular, hydrogen bonding was observed to be prevalent between the galactoside head 
group where the C4, C5 and C5 hydroxyl groups of the galactose sugar interacted 
extensively with Thr192. Stabilisation of the receptor by calcium ion (Ca1003) was 
observed to be quite significant where further interactions with two hydroxyl groups of 
the galactose molecule (C2 and C3) were observed. The above are in line with GalNac 
repector interactions, where the C3- and C4-hydroxyl groups are in coordination with the 
calcium ion (Stokmaier, 2010; Mamidyala et al., 2012). It has been suggested that  the 
hydroxyl group position plays an important role for the sugar moeities (D‟Souza et al., 
2013). Simultaneously, Ca1003 is observed to form hydrogen bonds with amino acids, 
Val190 and Glu196. These interactions with calcium have been suggested to be important 
in ASGP receptor binding; preferentially with the 3- and 4- hydroxyl groups (D‟Souza et 
al., 2012). Amino acids viz. Glu277, Glu279 and Ser163 also formed strong hydrogen 
bonds with the hydroxyl group on C2 of the galactose head. These extensive interactions 
clearly seem to result in steady and strong binding for the receptor. Hydrogen bonding of 
carboxyl and amide side-chains of aspartate and glutamine residues with C3 and C4 
hydroxyl groups have been reported to contribute to the strong ligand-binding interactions 






Figure 3.16 Docking of Sc6 galactoside at the active binding site of ASGP receptor and 







Figure 3.17 Docking of Sc9 galactoside at the active binding site of ASGP receptor and 






The acetylated Sc9 galactoside ligand comprised of the hydrophobic and bulkier acetoxy 
groups in place of the hydroxyl groups. Figure 3.17 shows the optimal docking model for 
this galactoside in the active site of the ASGP receptor. Their absence in this ligand was 
expected to result in compromised binding; however, contortion of the Sc9 ligand seemed 
to confer optimal docking conformation. Contrary to Sc6 docking disposition, extensive 
hydrogen bonds were observed to be with the triazine ring in the linker region of the 
ligand to the receptor amino acids viz. Ser163 and Glu277. The galactose head displayed 
minimal interactions and only involved Thr226 and Ser193. It must be noted that there 
were no interactions with the calcium ions in the active site – which is  reported to be a 
critical component for the active binding to the receptor. This would have led perhaps to a 
lesser degree of affinity to the receptor when compared to the Sc6 ligand.  It has been 
suggested that another critical factor that influences receptor-ligand binding relates to the 
stereochemical conformation of the ligands (Mamidyala et al., 2012; D‟Souza et al., 
2013). 
 
Calculated binding affinities revealed negative docking scores for Sc6 and Sc9 
galactoside ligands of –6.7 kCal/mol and –5.4 kCal/mol, respectively. These scores also 
corresponded with Glide scores reported by D‟Souza et al. (2013) for the D-galactose 
polymers including the arabinogalactan, comprising β(1─›3)D-galactose monomers. 
These also ranged from ˗5.5 kCal/mol to ˗9.79 kCal/mol. However, there was a 
marginally higher binding affinity calculated for the Sc6 ligand to the receptor compared 
to that of the acetylated Sc9. This was somewhat expected, given the reasons stated 
earlier. Additionally, the lower binding affinity of Sc9 galactoside can be explained in 
context of findings by Mamidyala et al. (2012),  By replacing the anomeric hydroxyl 
group of the galactose monomer with a β-4-methyl substituent, a 5-fold loss of affinity for 
the ASGP receptor was reported.  Thus the absence of interactions with the anomeric 





4 CHAPTER FOUR: CONCLUSION 
 
Cationic liposomes represent the most attractive non-viral gene carriers due to their 
biocompatibility, ease of manufacture and versatility in design. This is evident with a 
proportion of these vectors being used in various in vivo clinical trials, following the 
immunogenicity impasse presented by use of viral vectors. In contrast to their viral 
counterparts which have developed mechanisms to overcome cellular barriers, cationic 
liposomes and other non-viral vectors remain hindered by these obstacles presented in 
vivo (Schaffer and Lauffenburger, 2000; Mintzer and Simanek, 2009).  Furthermore, the 
process of internalisation and transfection has continued to be elusive. This is owing to 
the many factors that influence the liposome/DNA complex, including size, lamellarity, 
charge ratio and density. However, because these properties also influence each other, 
their defined roles are often obscured (Brgles et al., 2012). 
 
Design and synthesis of novel cationic lipids for an efficient gene delivery still presents a 
formidable task, and is often the result of trial and error (Mintzer and Simanek, 2009; 
Brgles et al., 2012). Composition thus plays an important role in design of liposomal 
formulations for gene delivery. Many cationic liposomal compositions entail the cationic 
lipid such as DOTAP/DOTMA, neutral lipid such as cholesterol and/or a co-lipid such as 
DOPE (Montier et al., 2008). The deployment of PEG has become common practice in 
the  design of stealth nano-therapeutics for sustained release of small molecules to nucleic 
acids. In fact, stealth liposomes have been employed in treatment of Kaposi sacorma and 
various other cancers e.g. breast, ovarian and solid tumours (Garg and Kokkoli, 2010; 
Allen and Cullis, 2013). Coating with PEG polymers has been shown to circumvent 
toxicity by forming a stabilising interface between the liposome and its environment 
resulting in increased circulation (Elsabahy et al., 2011). DOPE is proposed to improve 
transfection by promoting disruptions in the endosomal membrane (Aissaoui et al., 2002; 
Montier et al., 2008; Bhattacharya and Bajaj, 2009; Zhi et al., 2010).   
 
The targeting galactoside ligands viz. Sc6 and Sc9 were incorporated into liposomal 
formulations and comparatively evaluated for in vitro-in silico characteristics. 
Galactosylated cholesterol derivatives have been shown to exhibit lower cytotoxicity and 
improved transfection efficiency in HepG2 cells.  The higher transfection potential was 
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attributed to affinity of cellular receptors for galactosylated ligands (Kawakami et al., 
2000; Kawakami et al., 2007; Balazs and Godbey, 2011). Efficient gene delivery in vivo 
requires that complexed liposomes range between 50 nm and 200 nm (Ma et al., 2007; 
Bae and Park, 2011; Patil and Jadhav, 2014). The unPEGylated liposomes displayed 
larger than desirable size diameters showing tendencies to aggregate. However, the 
sterically stabilised PEGylated liposomal formulations displayed more compact size 
diameters ranging from 80 – 130 nm and near-neutral surface charges. Both Sc6- and 
Sc9-galactoside-bearing liposomes exhibited a capacity to bind DNA and provide some 
protection against nuclease digestion in serum, albeit partial. All lipoplexes were well-
tolerated by both the HEK293 and HepG2 cell lines as determined in cell viability 
studies. The acetylated SM3 lipoplex displayed the greatest transgene expression levels in 
both the HEK293 and HepG2 cell lines; however, it was not found to be a statistically 
significant effect. The mode of internalisation was unambiguously revealed to be via the 
ASGP receptor-mediation for the targeted liposomes bearing both galactoside ligands.  
 
Overall, these results confirmed the unequivocal relevance and potential of targeting by 
galactosylation in ASGP receptor mediated delivery. However, modifications such as in 
acetylation and PEGylation did not attest much significanct effect with respect to 
transfection in vitro. An equally important finding from the study pertained to the 
comparable transfection levels of the acetylated Sc9 and deacetylated Sc6 targeted 
lipoplexes in the HepG2 cell line, which were corroborated quite remarkably by the 
binding affinities calculated for both these ligands. This essentially reinforced the high 
correlation that clearly exists between in vitro and in silico studies.  
 
It is regrettable that most of the liposomes which have reached the various stages in 
clinical trials are untargeted, with much fewer targeted formulations having progressed 
that far. Nevertheless, the field of ligand-targeting continues to grow and presents many 
possibilites (Allen and Cullis, 2013). Future attempts at exploiting ligands for receptor-
mediated delivery should have a holistic approach. In performing molecular simulation 
studies, this could serve as a way to predict ligand receptor interactions and give some 
insight of the likely outcome in vitro. It is however, impossible to account more 
accurately for the properties that ultimately influence the disposition of ligands in vitro or 
in vivo. Despite this, the benefits of docking analyses cannot be undermined. Coupled 
with the invaluable in vitro experiments, optimisation of lipoplex formulations could be 
110 
 
achieved much more expediently this way.  This in turn, will ultimate for a more focused 
approach toward in vivo applications. In the long term, it could then allow for the design 
and development of multitude virtual libraries comprising small molecule therapeutics 
modified with suitable ligands (natural or synthetic) for enhanced specificity and binding 
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